0001144204-17-042654.txt : 20170814 0001144204-17-042654.hdr.sgml : 20170814 20170814083124 ACCESSION NUMBER: 0001144204-17-042654 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170814 DATE AS OF CHANGE: 20170814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellectar Biosciences, Inc. CENTRAL INDEX KEY: 0001279704 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043321804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36598 FILM NUMBER: 171027355 BUSINESS ADDRESS: STREET 1: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 BUSINESS PHONE: 617-244-1616 MAIL ADDRESS: STREET 1: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 FORMER COMPANY: FORMER CONFORMED NAME: NOVELOS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20050617 FORMER COMPANY: FORMER CONFORMED NAME: COMMON HORIZONS INC DATE OF NAME CHANGE: 20040211 10-Q 1 v472296_10q.htm FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

[mark one]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 30, 2017

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission File Number: 1-36598

CELLECTAR BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

04-3321804

(State or other jurisdiction of
incorporation or organization)

(IRS Employer

Identification No.)

3301 Agriculture Drive

Madison, Wisconsin 53716

(Address of principal executive offices)

(608) 441-8120

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	x
		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ¨ No x

Number of shares outstanding of the issuer’s common stock as of the latest practicable date: 13,922,170 shares of common stock, $0.00001 par value per share, as of August 9, 2017.

CELLECTAR BIOSCIENCES, INC.

FORM 10-Q INDEX

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 4.	Controls and Procedures	19

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	20
Item 1A.	Risk Factors	20
Item 6.	Exhibits	22

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

CELLECTAR BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

	June 30, 2017			December 31, 2016
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	8,313,073		$	11,444,619
Restricted cash		55,000			55,000
Prepaid expenses and other current assets		969,585			693,569
Total current assets		9,337,658			12,193,188
FIXED ASSETS, NET		1,576,244			1,444,058
GOODWILL		1,675,462			1,675,462
OTHER ASSETS		11,872			11,872
TOTAL ASSETS	$	12,601,236		$	15,324,580

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Current maturities of notes payable	$	—		$	86,591
Accounts payable and accrued liabilities		1,466,297			1,416,433
Derivative liability		119,600			127,125
Capital lease obligations, current portion		2,877			2,727
Total current liabilities		1,588,774			1,632,876
LONG-TERM LIABILITIES:
Deferred rent		144,151			146,583
Capital lease obligation, less current portion		3,772			5,249
Total long-term liabilities		147,923			151,832
TOTAL LIABILITIES		1,736,697			1,784,708
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.00001 par value; 7,000 shares authorized; none and 17 Series A issued and outstanding as of June 30, 2017 and December 31, 2016, respectively		—			875,572
Common stock, $0.00001 par value; 80,000,000 shares authorized; 13,462,170 and 10,368,325 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively		135			104
Additional paid-in capital		87,664,282			83,451,222
Accumulated deficit		(76,799,878	)		(70,787,026	)
Total stockholders’ equity		10,864,539			13,539,872
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	12,601,236		$	15,324,580

The accompanying notes are an integral part of these financial statements.

CELLECTAR BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016

COSTS AND EXPENSES:
Research and development	$	2,175,929		$	965,184		$	4,032,810		$	2,004,638
General and administrative		1,040,540			1,367,726			1,995,896			2,328,981
Total costs and expenses		3,216,469			2,332,910			6,028,706			4,333,619

LOSS FROM OPERATIONS		(3,216,469	)		(2,332,910	)		(6,028,706	)		(4,333,619	)

OTHER INCOME:
Gain on revaluation of derivative warrants		90,000			198,370			7,525			3,023,092
Interest income, net		4,941			1,637			8,328			2,187
Total other income, net		94,941			200,007			15,853			3,025,279
NET LOSS	$	(3,121,528	)	$	(2,132,903	)	$	(6,012,853	)	$	(1,308,340	)
BASIC AND DILUTED NET LOSS PER COMMON SHARE	$	(0.23	)	$	(0.49	)	$	(0.47	)	$	(0.50	)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE		13,461,994			4,328,303			12,740,149			2,617,341

The accompanying notes are an integral part of these financial statements.

CELLECTAR BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Six Months Ended June 30,
	2017			2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(6,012,853	)	$	(1,308,340	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization		188,325			181,461
Stock-based compensation expense		396,760			222,887
Gain on revaluation of derivative warrants		(7,525	)		(3,023,092	)
Changes in:
Accounts payable and accrued liabilities		49,864			140,838
Prepaid expenses and other current assets		(263,169	)		66,999
Other assets and liabilities		(2,432	)		(651	)
Cash used in operating activities		(5,651,030	)		(3,719,898	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of fixed assets		(320,510	)		(4,207	)
Cash used in investing activities		(320,510	)		(4,207	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on notes payable		(86,591	)		(121,330	)
Proceeds from issuance of common stock, net of underwriting issuance costs		—			7,371,121
Cash paid for issuance costs		—			(150,633	)
Proceeds from exercise of warrants		2,940,759			652,516
Cash paid for reverse stock split fractional shares		—			(594	)
Change in deferred issuance costs		(12,847	)		38,569
Payments on capital lease obligations		(1,327	)		(1,191	)
Cash provided by financing activities		2,839,994			7,788,458
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(3,131,546	)		4,064,353
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		11,444,619			3,857,791
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	8,313,073		$	7,922,144

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest expense	$	364		$	2,753
Reclassification to equity for warrants that are no longer derivative instruments	$	—		$	1,392,000

The accompanying notes are an integral part of these financial statements.

CELLECTAR BIOSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN

Cellectar Biosciences, Inc. (the “Company”) is a biopharmaceutical company developing compounds for the treatment of cancer. The Company’s headquarters are located in Madison, Wisconsin.

The Company is subject to a number of risks similar to those of other small pharmaceutical companies. Principal among these risks are dependence on key individuals, competition from substitute products and larger companies, the successful development and marketing of its products in a highly regulated environment and the need to obtain additional financing necessary to fund future operations.

The accompanying financial statements have been prepared on a basis that assumes the Company will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has devoted substantially all of its efforts toward research and development and has, during the six months ended June 30, 2017, generated an operating loss of approximately $6,029,000. The Company expects that it will continue to generate operating losses for the foreseeable future.

The Company believes that its cash balance at June 30, 2017 is adequate to fund operations at budgeted levels into second quarter 2018. The Company’s ability to execute its operating plan beyond second quarter 2018 depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. The Company plans to continue actively pursuing financing alternatives, but there can be no assurance that it will obtain the necessary funding, raising substantial doubt about the Company’s ability to continue as a going concern within one year of the date these financial statements are issued. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The accompanying condensed consolidated balance sheet as of December 31, 2016 has been derived from audited financial statements. The accompanying unaudited condensed consolidated balance sheet as of June 30, 2017, the condensed consolidated statements of operations for the three months and six months ended June 30, 2017 and 2016, the condensed consolidated statements of cash flows for the six months ended June 30, 2017 and 2016 and the related interim information contained within the notes to the condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions, rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments which are of a nature necessary for the fair presentation of the Company’s consolidated financial position at June 30, 2017 and consolidated results of its operations for the three months and six months ended June 30, 2017 and 2016, and its cash flows for the six months ended June 30, 2017 and 2016. The results for the six months ended June 30, 2017 are not necessarily indicative of future results.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes thereto included in the Company’s Form 10-K for the fiscal year ended December 31, 2016, which was filed with the SEC on March 15, 2017.

Principles of Consolidation — The consolidated financial statements include the accounts of the Company and the accounts of its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.

Restricted Cash — The Company accounts for cash that is restricted for other than current operations as restricted cash. Restricted cash at June 30, 2017 and December 31, 2016 consisted of a certificate of deposit of $55,000 required under the Company’s lease agreement for its Madison, Wisconsin facility.

Goodwill — Goodwill is not amortized, but is required to be evaluated for impairment annually or whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company evaluates goodwill for impairment annually in the fourth fiscal quarter and additionally on an interim basis if an event occurs or there is a change in circumstances, such as a decline in the Company’s stock price or a material adverse change in the business climate, which would more likely than not reduce the fair value of the reporting unit below its carrying amount. No such event or change in circumstances occurred; therefore no changes in goodwill were made during the six months ended June 30, 2017 and 2016.

In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill. The standard streamlines the methodology for calculating whether goodwill is impaired based upon whether the carrying amount of goodwill exceeds the reporting unit’s fair value. ASU 2017-04 applies to public business entities and those other entities that have goodwill reported in their financial statements and have not elected the private company alternative for the subsequent measurement of goodwill and is effective for annual and interim reporting periods beginning after December 15, 2019, with early adoption permitted. The Company does not expect that the adoption of this standard will have a material effect on its financial statements.

Impairment of Long-Lived Assets — Long-lived assets other than goodwill consist primarily of fixed assets, which we periodically evaluate for potential impairment. Whenever events or circumstances change, an assessment is made as to whether there has been an impairment in the value of long-lived assets by determining whether projected undiscounted cash flows generated by the applicable asset exceed its net book value as of the assessment date. No such event or change in circumstances occurred; therefore no such impairment occurred during the six months ended June 30, 2017 and 2016.

Stock-Based Compensation — The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for awards that are not performance-based is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Awards of stock that are not performance-based are valued at the fair market value on the date of the grant and are amortized over the service period of the award. Non-employee stock-based compensation is accounted for in accordance with the guidance of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) Topic 505, Equity. As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.

Fair Value of Financial Instruments — The guidance under FASB ASC Topic 825, Financial Instruments, requires disclosure of the fair value of certain financial instruments. Financial instruments in the accompanying financial statements consist of cash equivalents, accounts payable and long-term obligations. The carrying amount of cash equivalents and accounts payable approximate their fair value due to their short-term nature. The carrying value of remaining long-term obligations, including the current portion, approximates fair value because the fixed interest rate approximates current market interest rates available on similar instruments.

Derivative Instruments — The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain a certain type of cash settlement feature, “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was 533,065 at June 30, 2017 and December 31, 2016. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At June 30, 2017 and December 31, 2016, these warrants represented the only outstanding derivative instruments issued or held by the Company.

Leases — In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is currently evaluating the method of adoption and the impact of adopting ASU 2016-02 on its results of operations, cash flows and financial position.

2. FAIR VALUE

In accordance with the Fair Value Measurements and Disclosures Topic of the FASB ASC 820, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.

Level 1: Input prices quoted in an active market for identical financial assets or liabilities.

Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.

Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The Company issued warrants to purchase an aggregate of 82,500 common shares in a February 2013 public offering (the “February 2013 Public Offering Warrants”). On February 20, 2014, 27,500 of the February 2013 Public Offering Warrants expired. On May 20, 2016, 16,250 warrants were exercised. The remaining 38,750 warrants are classified within the Level 3 hierarchy.

In August 2014, as part of an underwritten public offering, the Company issued 494,315 warrants to purchase common stock (the “August 2014 Warrants”). The August 2014 Warrants are listed on the Nasdaq Capital Market under the symbol “CLRBW,” however, there are certain periods where trading volume is low; therefore, they are classified as Level 2 within the hierarchy.

The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of June 30, 2017 and December 31, 2016:

	June 30, 2017
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	18,600	$	18,600
August 2014 Warrants		—		101,000		—		101,000
Total	$	—	$	101,000	$	18,600	$	119,600

	December 31, 2016
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	27,125	$	27,125
August 2014 Warrants		—		100,000		—		100,000
Total	$	—	$	100,000	$	27,125	$	127,125

In order to estimate the value of the February 2013 Public Offering Warrants considered to be derivative instruments, the Company uses a modified option-pricing model together with assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rates, volatility, the contractual term of the warrants, future financing requirements and dividend rates. The future financing estimates are based on the Company’s estimates of anticipated cash requirements over the term of the warrants as well as the frequency of required financings based on its assessment of its historical financing trends and anticipated future events. Due to the nature of these inputs and the valuation technique utilized, these warrants are classified within the Level 3 hierarchy.

The following table summarizes the modified option-pricing assumptions used:

	Six Months Ended June 30, 2017			Twelve Months Ended December 31, 2016
Volatility		76	%		92.72-134%
Risk-free interest rate		1.21	%		0.53-1.15%
Expected life (years)		0.64			1.14-1.89
Dividend		0	%		0%

During fiscal year 2016, the Company had warrants outstanding for part of the year that were considered financial instruments. Those warrants were either extinguished or amended such that they were no longer considered financial instruments as of December 31, 2016, and were, therefore, not financial instruments during the three or six months ended June 30, 2017. The following table summarizes the modified option-pricing assumptions used for the period they were considered financial instruments:

	Twelve Months Ended December 31, 2016
Volatility		89.73	%
Risk-free interest rate		1.65	%
Expected life (years)		4.50
Dividend		0	%

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy:

	Six Months Ended June 30, 2017			Twelve Months Ended December 31, 2016
Beginning balance – Fair value	$	27,125		$	2,067,000
Reclassification to equity for warrants that are no longer derivative liabilities		—			(1,392,429	)
Gain on derivatives resulting from change in fair value or extinguishment		(8,525	)		(647,446	)
Ending balance – Fair value	$	18,600		$	27,125

In order to estimate the fair value of the August 2014 Warrants, the Company calculated the weighted average closing price for the trailing 10 day period with trades that ended on the balance sheet date.

3. STOCKHOLDERS’ EQUITY

November 2016 Underwritten Offering

On November 23, 2016, the Company entered into an Underwriting Agreement with Ladenburg Thalmann & Co. Inc., as representative of the several underwriters named therein, in connection with the Company’s Registration Statement on Form S-1. Pursuant to the Underwriting Agreement, the Company agreed to sell to the Underwriter 800,000 shares of common stock, 68 shares of Series A preferred stock convertible into 4,533,356 shares of common stock, and Series C warrants to purchase 5,333,356 shares of common stock, plus up to an additional 800,000 shares of common stock and Series C warrants to purchase up to an additional 800,000 shares of common stock in the event of the exercise by the Underwriter of its over-allotment option. The public offering price of a share of common stock together with a Series C warrant to purchase one share of common stock was $1.50. The public offering price to purchase one share of Series A preferred stock, each of which is convertible into 66,667 shares of common stock, together with a Series C warrant to purchase 66,667 shares of common stock was $100,000. The preferred stock was non-voting, had no dividend rights (except to the extent dividends were also paid on common stock), liquidation preference, or other preferences over common stock. The Series C warrants have an exercise price of $1.50 per share, and are exercisable for five years from the date of issuance. The net proceeds were allocated to each security based upon the pro-rata values of the underlying common stock and a Black-Scholes valuation of the warrants.

The sale of securities pursuant to the Underwriting Agreement, including the entire over-allotment option, closed on November 29, 2016 (the “November 2016 Underwritten Offering”). Gross proceeds were $9.2 million with net proceeds to the Company of approximately $8.3 million.

As of December 31, 2016, 17 shares of Series A preferred stock were outstanding. During the six months ended June 30, 2017, all 17 shares were converted into 1,133,339 shares of common stock.

During the six months ended June 30, 2017, Series C warrants representing 1,960,506 shares of common stock were exercised by the holders, for proceeds of $2,940,759.

April 2016 Underwritten Offering

On April 15, 2016 the Company entered into an Underwriting Agreement with Ladenburg Thalmann & Co., Inc. in connection with the Company’s Registration Statement on Form S-1. Pursuant to the Underwriting Agreement, the Company agreed to sell to the Underwriter 1,378,364 shares of common stock, Series B prefunded warrants to purchase 1,908,021 shares of common stock and Series A warrants to purchase 3,286,385 shares of common stock, plus up to an additional 492,957 shares of common stock and Series A warrants to purchase up to an additional 492,957 shares of common stock in the event of the exercise by the Underwriter of its over-allotment option. The public offering price of a share of common stock together with a Series A warrant to purchase one share of common stock was $2.13. The public offering price of a Series B pre-funded warrant to purchase one share of common stock together with a Series A warrant to purchase one share of common stock was $2.12. The Series B pre-funded warrants had an exercise price of $0.01 per share, were immediately exercisable and did not expire. The Series A warrants have an exercise price of $3.04 per share, are exercisable for five years from the date of issuance, and are callable by the Company under certain circumstances.

On April 20, 2016, the Company closed on the underwritten public offering (the “April 2016 Underwritten Offering”) of 1,871,321 shares of its common stock and Series B pre-funded warrants to purchase 1,908,021 shares of common stock, plus the issuance of Series A warrants to purchase 3,779,342 shares of common stock, reflecting the exercise in full of the Underwriter’s over-allotment option. Prior to June 30, 2016, all of the Series B pre-funded warrants were exercised. The gross proceeds of the offering amounted to approximately $8.0 million with net proceeds to the Company of approximately $7.2 million.

Warrant Restructuring

On April 13, 2016, the Company entered into an exchange and amendment agreement (the “Warrant Restructuring Agreement”). Pursuant to the Warrant Restructuring Agreement, the Company agreed with the holders of 2015 Series A warrants that upon the consummation of the 2016 Underwritten Offering, the exercise price of the 2015 Series A warrants would be reduced to the public offering price per share of the shares of common stock sold in this offering and that the warrants would be amended such that the exercise price would no longer be subject to adjustment in connection with future equity offerings we may undertake. In consideration of this amendment, the Company agreed to issue to each of those holders a new warrant to purchase an additional number of shares of common stock equal to twice the number of shares of common stock underlying the 2015 Series A Warrants held by them (the “Incremental Series A Warrants”). As a result, the 2015 Series A warrants and the Incremental Series A Warrants have an exercise price equal to $2.13 (the public offering price of the shares of common stock sold in the 2016 Underwritten Offering).

2016 Reverse Stock Split and Recapitalization

At a special meeting held on February 8, 2016, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to effect a reverse split of the Company’s common stock at a ratio between 1:5 to 1:10 in order to ensure that adequate authorized but unissued shares would be available for anticipated future financings, and to satisfy requirements for the continued listing of the Company’s common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue remained unchanged at 40,000,000. The Company’s stockholders further authorized the board of directors to determine the ratio at which the reverse split would be effected by filing an appropriate amendment to the Company’s certificate of incorporation. The board of directors authorized the ratio of the reverse split and corresponding reduction in authorized shares on February 24, 2016, and effective at the close of business on March 4, 2016, the Company’s certificate of incorporation was amended to effect a 1-for-10 reverse split of the Company’s common stock (the “2016 Reverse Split”). All share and per share numbers included in these consolidated financial statements give effect to the 2016 Reverse Split.

Common Stock Warrants

The following table summarizes information with regard to outstanding warrants to purchase common stock as of June 30, 2017:

Offering	Number of Shares Issuable Upon Exercise of Outstanding Warrants		Exercise Price			Expiration Date
November 2016 Public Offering Series C		4,172,850	$	1.50		November 29, 2021
April 2016 Underwritten Registered Series A		3,626,942	$	3.04		April 20,2021
October 2015 Incremental Series A		300,006	$	2.13		October 20,2021
October 2015 Private Placement Series A		86,365	$	2.13		April 1, 2021
October 2015 Offering – Placement Agent		3,750	$	28.30		October 1, 2020
August 2014 Public Offering ⁽¹⁾		504,019	$	46.80		August 20, 2019
February 2013 Public Offering ⁽¹⁾		38,750	$	1.50	⁽²⁾	February 20, 2018
February 2013 Public Offering – Placement Agents		3,854	$	125.00		February 4, 2018
November 2012 Private Placement		5,000	$	250.00		November 2, 2017
Total		8,741,536

(1)

(2)

Due to the issuance of common stock at $1.50 per share as part of the November 2016 Underwritten Offering, the remaining outstanding warrants issued as part of the February 2013 Public Offering were adjusted to reflect the revised exercise price of $1.50 each.

Reserved Shares

The following shares were reserved for future issuance upon exercise of stock options and grants, preferred stock conversions and warrants:

	June 30, 2017		December 31, 2016

Warrants		8,741,536		10,716,952
Preferred stock		—		1,133,339
Stock options and grants		1,018,733		471,433
Total number of shares reserved for future issuance		9,760,269		12,321,724

4. NOTES PAYABLE

During the quarter ended March 31, 2017, the two loans with initial principal amounts totaling $450,000 from the Wisconsin Economic Development Corporation, dated September 15, 2010, were paid in full.

5. STOCK-BASED COMPENSATION

Accounting for Stock-Based Compensation

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock grants and stock option grants and recorded in connection with stock options granted to non-employee consultants:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016

Employee and director stock and stock option grants:
Research and development	$	40,072	$	13,335	$	56,720	$	24,370
General and administrative		191,014		106,606		340,040		198,855
		231,086		119,941		396,760		223,225

Non-employee consultant stock option grants:
Research and development		—		28		—		(338	)

Total stock-based compensation	$	231,086	$	119,969	$	396,760	$	222,887

Assumptions Used In Determining Fair Value for Stock Options

Valuation and amortization method. The fair value of each stock option award is estimated on the grant date using the Black-Scholes option-pricing model. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. The estimated fair value of the non-employee options is amortized to expense over the period during which a non-employee is required to provide services for the award (usually the vesting period).

Volatility. The Company estimates volatility based on an average of (1) the Company’s historical volatility since its common stock has been publicly traded and (2) review of volatility estimates of publicly held drug development companies with similar market capitalizations.

Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.

Expected term. The expected term of stock options granted is based on an estimate of when options will be exercised in the future. The Company applied the simplified method of estimating the expected term of the options, as described in the SEC’s Staff Accounting Bulletins 107 and 110, as the historical experience is not indicative of the expected behavior in the future. The expected term, calculated under the simplified method, is applied to groups of stock options that have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. The Company applied the simplified method to non-employees who have a truncation of term based on termination of service and utilizes the contractual life of the stock options granted for those non-employee grants which do not have a truncation of service.

Forfeitures. The Company records stock-based compensation expense only for those awards that are expected to vest. A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. An annual forfeiture rate of 2% was applied to all unvested options for the six months ended June 30, 2017 and for the year ended December 31, 2016. Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.

Exercise prices for all grants made during the six months ended June 30, 2017 and 2016 were equal to the market value of the Company’s common stock on the date of grant.

Stock Option Activity

A summary of stock option activity is as follows:

	Number of Shares Issuable Upon Exercise of Outstanding Options		Weighted Average Exercise Price		Weighted Average Remaining Contracted Term in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2016		471,433	$	7.59
Granted		87,300	$	1.93
Expired		—	$	—
Forfeited		—	$	—
Outstanding at June 30, 2017		558,733	$	6.70

Vested, June 30, 2017		146,360	$	16.31		8.53	$	13,819
Unvested, June 30, 2017		412,373	$	3.30		9.07	$	27,641
Exercisable at June 30, 2017		146,360	$	16.31		8.53	$	13,819

The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the estimated per-share fair value of common stock at the end of the respective period and the exercise price of the underlying options. There have been no options exercised during 2017. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.

Stock Grants

During the three months ended June 30, 2017, the Company issued a total of 460,000 shares of restricted common stock to members of the executive team. The restricted stock was granted at a price of either $2.08 or $2.10, which in each case were the closing prices of the stock on the dates of issuance, and vests in equal annual amounts over three years. The related expense will be amortized ratably over the vesting period.

The unvested portion of the restricted stock grants is not considered to be outstanding for accounting purposes; therefore, the related shares are not included in the earnings per share calculation or the shares reported as outstanding on the balance sheet, as of or for the periods ended June 30, 2017. Note that such shares are considered outstanding from a legal perspective as of the date of grant.

Unrecognized Compensation Cost

As of June 30, 2017, there was approximately $1,740,000 of total unrecognized compensation cost related to unvested stock-based compensation arrangements. Of this total amount, the Company expects to recognize approximately $408,000, $736,000, $524,000 and $72,000 during 2017, 2018, 2019 and 2020 respectively. The Company’s expense estimates are based upon the expectation that all unvested stock grants and stock options will vest in the future, less the forfeiture rate discussed above. The weighted-average grant-date fair value of vested and unvested stock grants and stock options outstanding at June 30, 2017 was $12.42 and $2.37, respectively.

6. INCOME TAXES

The Company accounts for income taxes in accordance with the liability method of accounting. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax basis of assets and liabilities, and net operating loss carryforwards (NOLs), using the enacted tax rates. Deferred income tax expense or benefit is based on changes in the asset or liability from period to period. The Company did not record a provision or benefit for federal, state or foreign income taxes for the six months ended June 30, 2017 or 2016 because the Company has experienced losses on a tax basis since inception. Because of the continuing losses and uncertainty associated with the utilization of the NOLs in the future, management has provided a full allowance against the value of its gross deferred tax assets.

The Company also accounts for the uncertainty in income taxes related to the recognition and measurement of a tax position taken or expected to be taken in an income tax return. The Company follows the applicable accounting guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition related to the uncertainty in income tax positions. No uncertain tax positions have been identified.

7. NET LOSS PER SHARE

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of shares of common stock and the dilutive potential common stock equivalents then outstanding. Potential common stock equivalents consist of stock grants, stock options and warrants. Since there is a net loss attributable to common stockholders for the three months and six months ended June 30, 2017 and 2016, the inclusion of common stock equivalents in the computation for those periods would be antidilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented.

The following potentially dilutive securities have been excluded from the computation of diluted net loss per share since their inclusion would be antidilutive:

	Six Months Ended June 30,
	2017		2016
Warrants		8,741,536		4,629,842
Stock options and grants		1,018,733		397,882

8. COMMITMENTS AND CONTINGENCIES

The Company is involved in legal matters and disputes in the ordinary course of business. We do not anticipate that the outcome of such matters and disputes will materially affect the Company’s financial statements.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This quarterly report on Form 10-Q includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. For this purpose, any statements contained herein regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management, other than statements of historical facts, are forward-looking statements. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those disclosed in the forward-looking statements we make. These important factors include our significant accounting estimates, such as those for amounts due to clinical research organizations, and clinical investigators and the risk factors set forth in our annual report on Form 10-K and in Part II below under the caption “Risk Factors”. Although we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and readers should not rely on those forward-looking statements as representing our views as of any date subsequent to the date of this quarterly report.

Overview

Cellectar Biosciences, Inc. (the Company) is a clinical stage biopharmaceutical company focused on the development of targeted phospholipid drug conjugates (PDCs) for the treatment of cancer. The Company’s research and development program is based on its proprietary PDC cancer targeting delivery platform. The delivery platform possesses the potential for the discovery and development of a broad range of cancer targeting agents. The Company’s pipeline is comprised of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic PDC’s. The Company’s research and development resources are focused on the clinical advancement of its therapeutic PDC’s.

Our Company’s core strategy is to leverage our industry leading PDC, proprietary cancer targeting delivery platform to generate capital, supplement internal resources and accelerate and broaden product candidate clinical development through strategic asset acquisitions and research collaborations.

Our shares are listed on the Nasdaq® Capital Market under the symbol CLRB; prior to August 15, 2014, our shares were quoted on the OTCQX® marketplace, and prior to February 12, 2014 were quoted under the symbol NVLT.

Our PDC platform is based on our cancer-targeting and delivery technology which provides selective delivery of a diverse range of oncologic payloads to cancer cells and cancer stem cells. By linking various drug payloads to our proprietary phospholipid ether cancer-targeting vehicle, we believe we can create PDCs with the potential to provide highly targeted delivery of chemotherapeutic and radiotherapeutic payloads to a broad range of cancers. As a result, our PDC platform has the potential to improve the therapeutic indices of drug payloads and enhance or maintain efficacy while minimizing the off-target and toxic side effects that frequently occur with typical cancer therapies. The Company is currently focused on the development of its lead therapeutic product candidate, CLR 131. Additionally, the Company is executing the pre-clinical evaluation and development of its CLR CTX Chemotherapeutic PDC program with both internal and external resources.

CLR 131 is a small-molecule, cancer-targeting radiotherapeutic PDC that is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells. CLR 131 is our lead therapeutic PDC product candidate and is currently being evaluated in both Phase 1 and Phase 2 clinical studies. The Phase 1 clinical study is a standard three by three dose escalation safety study in patients with relapse or refractory multiple myeloma. Multiple myeloma is the second most common hematologic cancer and an incurable cancer of plasma cells. This cancer type was selected for clinical, regulatory and commercial rationales, including multiple myeloma’s highly radiosensitive nature, and continued unmet medical need in the relapse/refractory setting. The primary goals of the Phase 1 study are to assess the compound’s safety and tolerability in patients with relapsed or refractory multiple myeloma. Secondary objectives include establishment of a recommended Phase 2 dose, both with and without dexamethasone, as well as an assessment of therapeutic activity, including surrogate efficacy markers, progression free survival (PFS) and overall survival. The Investigational New Drug (IND) application was accepted by the U.S. Food and Drug Administration (FDA) in March 2014. In December 2014, the FDA granted orphan drug designation for CLR 131 for the treatment of multiple myeloma. The Phase 1 study was initiated in April 2015 and we announced favorable safety results from the first patient cohort in January 2016. The study’s Data Monitoring Committee (DMC), unanimously agreed to allow an increase in the dose of CLR 131 by 50% and advancement into the second cohort. The DMC reviewed Cohort 2 patient safety data in September 2016, and unanimously agreed to an increase in the dose by 33% and advancement to Cohort 3. In February 2017, the DMC unanimously determined the safety profile was again favorable in Cohort 3 and that it was acceptable to advance into Cohort 4 with an increase in dose by 20%. Surrogate markers of efficacy, including M protein, Free Light Chain (FLC), Progression Free Survival (PFS), and Overall Survival (OS), are also captured as secondary objectives of this Phase 1 study. In July 2016, the Company was awarded a $2,000,000 National Cancer Institute Fast-Track Small Business Innovation Research (SBIR) grant to further advance CLR 131. The funds are supporting a Phase 2 study the Company initiated in March 2017 to further define the clinical benefits of CLR 131 in multiple myeloma and other rare hematologic malignancies.

The Company is exploring the creation of additional PDCs ranging from newly discovered to well-characterized chemotherapeutic payloads under its CLR CTX Chemotherapeutic PDC program. The objective of our CTX program is to develop PDC chemotherapeutics through conjugation of our delivery vehicle and non-targeted anti-cancer agents to improve therapeutic indices and expand potential indications through the targeted delivery of chemotherapeutic payloads. Initial CTX product candidates include CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX; all are small-molecule, cancer-targeting chemotherapeutics in pre-clinical research. These PDCs are designed to selectively deliver paclitaxel, a chemotherapeutic payload to cancer cells and cancer stem cells increasing the therapeutic index of paclitaxel as a monotherapy. Each of our paclitaxel PDC’s have been evaluated in vitro to demonstrate formulation stability and CLR 1602-PTX is currently being studied in vivo to further explore the PDC’s cancer targeting selectivity. In December of 2015, the Company entered into a research collaboration for our PDC technology with Pierre Fabre laboratories, the third largest French pharmaceutical company. The objective of the research collaboration is to co-design a library of PDC’s employing Pierre Fabre’s chemotherapeutics in combination with our proprietary cancer targeting delivery vehicle. The newly developed PDC’s may provide enhanced therapeutic indices to otherwise highly potent, non-targeted payloads through the targeted delivery to cancer cells provided by our cancer targeted delivery vehicle.

CLR 125 is a cancer-targeting radiotherapeutic currently under pre-clinical investigation for the treatment of micrometastatic disease. Similar to CLR 131, the selective uptake and retention of CLR 125 has been observed in malignant tissues during pre-clinical studies. Preclinical evaluation of this molecule was completed in June 2016 as part of the Phase 1 portion of an NCI SBIR award and demonstrated favorable biodistribution, tolerability, and dose response.

The Company’s product pipeline also includes a diagnostic imaging agent, CLR 124, a Phase 2-ready asset, as well as our 1500 series of optical imaging agents, including 1502, a Phase 1-ready asset. Although these are intriguing and potentially clinically useful compounds, at this time the Company has prioritized the development of its therapeutic assets.

We believe our PDC platform has potential to provide targeted delivery of a diverse range of oncologic payloads, as exemplified by the product candidates listed above, that may result in improvements upon current standard of care (SOC) for the treatment of a broad range of human cancers.

Results of Operations

Research and development expense. Research and development expense consists of costs incurred in identifying, developing and testing, and manufacturing product candidates, which primarily include salaries and related expenses for personnel, costs of our research and manufacturing facility, cost of manufacturing materials and contract manufacturing fees paid to contract research organizations, fees paid to medical institutions for clinical trials, and costs to secure intellectual property. The Company analyzes its research and development expenses based on four categories as follows: clinical projects, preclinical projects, chemistry and manufacturing costs, and general fixed and overhead costs that are not allocated to the functional project costs, including personnel costs, facility costs, related overhead costs and patent costs.

General and administrative expense. General and administrative expense consists primarily of salaries and other related costs for personnel in executive, finance and administrative functions. Other costs include insurance, costs for public company activities, investor relations, directors’ fees and professional fees for legal and accounting services.

Six Months Ended June 30, 2017 and 2016

Research and Development. Research and development expense for the six months ended June 30, 2017 was approximately $4,033,000 (comprised of $740,000 in clinical project costs, $261,000 of manufacturing and related costs, $220,000 of preclinical project costs and $2,812,000 in general research and development costs) compared to approximately $2,005,000 (comprised of $378,000 in clinical project costs, $135,000 of manufacturing and related costs and $1,492,000 in general research and development costs) for the six months ended June 30, 2016. The overall increase in research and development expense of approximately $2,028,000, or 100%, was due primarily to the initiation of the Phase 2 clinical study of CLR 131 in hematologic malignancies and the establishment of a secondary manufacturing capability, the combination of which represented approximately $1,560,000 of the increase. Additionally, increases in: personnel and related travel of approximately $300,000; purchased services related to pre-clinical studies of $177,000; and equipment and building repairs and maintenance of approximately $50,000 drove the remainder of the increase, which was slightly offset by reduced spending related to the SBIR funding of approximately $91,000.

General and Administrative. General and administrative expense for the six months ended June 30, 2017 was approximately $1,996,000, compared to approximately $2,329,000 in the six months ended June 30, 2016. The approximately $333,000 or 14% decrease was due to an approximately $400,000 decrease in purchased services, primarily legal, accounting and consulting fees, and a decrease of approximately $52,000 in public company and printing-related expenses, partially offset by an increase in personnel costs of approximately $155,000.

Gain on Derivative Warrants. We recorded a gain on derivative warrants of approximately $8,000 and $3,023,000 in the six months ended June 30, 2017 and 2016, respectively. These amounts represent the change in fair value, during the respective periods, of outstanding warrants which contain a certain type of cash settlement feature, or “down-round” anti-dilution provisions whereby the number of shares for which the warrants are exercisable or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise prices of the warrants. The fluctuations we experienced in historical periods have been substantially reduced as a result of the renegotiation or extinguishment of a significant portion of the formerly liability-classified warrants that are now classified as equity.

Interest income, net. Interest income, net, for the six months ended June 30, 2017 was approximately $8,000 related to the returns on the Company’s cash, which has been placed in high quality short-term investments when possible. For the six months ended June 30, 2016, the approximately $2,000 of interest income, net, included approximately $3,000 of interest income partially offset by approximately $1,000 of interest expense related to the accrual of interest on the then outstanding debt with the Wisconsin Economic Development Corporation.

Liquidity and Capital Resources

We have financed our operations since inception primarily through the sale of equity and debt securities. As of June 30, 2017, we had approximately $8,313,000 in cash and cash equivalents. To that date, we have raised capital aggregating approximately $167 million.

During the six months ended June 30, 2017, we reported net loss of approximately $6,013,000, while using approximately $5,651,000 in cash in operations. The net loss included an approximately $8,000 gain on the revaluation of derivative warrants, approximately $397,000 in stock-based compensation expense and approximately $188,000 in depreciation and amortization expense. After adjustment for these non-cash items, changes in working capital used approximately $215,000 of cash, of which $50,000 was the result of the timing of payments of accounts payable and accrued expenses and the remainder was an increase in prepaid and other assets of approximately $265,000. Also during this period, Series C warrants representing 1,960,506 shares of common stock were exercised by the holders, generating proceeds of approximately $2,941,000.

The accompanying consolidated financial statements have been prepared on a basis that assumes that we will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. During the six months ended June 30, 2017, we generated an operating loss of approximately $6,029,000 and we expect that we will continue to generate operating losses for the foreseeable future.

On November 29, 2016, the Company closed on an underwritten public offering (the “November 2016 Underwritten Offering”) of 1.6 million shares of common stock, 68 shares of Series A preferred stock convertible into 4,533,336 shares of common stock, and Series C warrants to purchase 6.3 million shares of common stock, reflecting the exercise in full of the Underwriter’s over-allotment option. The gross proceeds of the offering amounted to $9.2 million with net proceeds to the Company of approximately $8.3 million.

On April 20, 2016, the Company closed on its underwritten public offering of approximately 1.87 million shares of its common stock and Series B pre-funded warrants to purchase approximately 1.91 million shares of common stock, plus the issuance of Series A warrants to purchase approximately 3.78 million shares of common stock, reflecting the exercise in full of the Underwriter’s over-allotment option (the “April 2016 Underwritten Offering”). The gross proceeds of the offering amounted to approximately $8.0 million with net proceeds to the Company of approximately $7.2 million.

We believe our June 30, 2017 cash balance of approximately $8,313,000 is adequate to fund operations into the second quarter of 2018. Our ability to execute our operating plan beyond that time depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. We have, in the past, successfully completed multiple rounds of financings, but due to market conditions and other factors, including our development stage, the proceeds we have been able to secure have been less than the amounts we sought to obtain. We plan to actively pursue all available financing alternatives; however, we have not entered into negotiations for any such transactions and there can be no assurance that we will obtain the necessary funding. Other than the uncertainties regarding our ability to obtain additional funding, there are currently no known trends, demands, commitments, events or uncertainties that are likely to materially affect our liquidity.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. Based on our management’s evaluation (with the participation of our principal executive officer and principal financial officer), as of June 30, 2017, our management has concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

Changes in internal control over financial reporting. There have not been any significant changes in the Company’s internal control over financial reporting.

The Chief Executive Officer and the Audit Committee perform significant roles in ensuring the accuracy and completeness of our financial reporting and the effectiveness of our disclosure controls and procedures. We have not identified any changes that occurred during the Company’s fiscal quarter ended June 30, 2017 that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Important Considerations. Any system of controls, however well designed and operated, can provide only reasonable, and not absolute assurance that the objectives of the system are met. In addition, the design of any control system is based in part on certain assumptions about the likelihood of future events. The effectiveness of our disclosure controls and procedures is subject to various inherent limitations, including cost limitations, judgments used in decision making, assumptions about the likelihood of future events, the soundness of our systems, the possibility of human error, and the risk of fraud. Because of these and other inherent limitations of control systems, there can be no assurance that any system of disclosure controls and procedures will be successful in achieving its stated goals, including but not limited to preventing all errors or fraud or in making all material information known in a timely manner to the appropriate levels of management, under all potential future conditions, regardless of how remote.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

We will require additional capital in order to continue our operations, and may have difficulty raising additional capital.

We expect that we will continue to generate significant operating losses for the foreseeable future. At June 30, 2017, our consolidated cash balance was approximately $8.3 million. We believe our cash balance at June 30, 2017, is adequate to fund operations into the second quarter of 2018. We will require additional funds to conduct research and development, establish and conduct clinical and preclinical trials, establish commercial-scale manufacturing arrangements and provide for the marketing and distribution of our products. Our ability to execute our operating plan depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. We plan to actively pursue financing alternatives. However, there can be no assurance that we will obtain the necessary funding in the amounts we seek or that it will be available on a timely basis or upon terms acceptable to us. If we obtain capital by issuing debt or preferred stock, the holders of such securities would likely obtain rights that are superior to those of holders of our common stock.

Our capital requirements and our ability to meet them depend on many factors, including:

the number of potential products and technologies in development;

continued progress and cost of our research and development programs;

progress with preclinical studies and clinical trials;

the time and costs involved in obtaining regulatory clearance;

costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims;

costs of developing sales, marketing and distribution channels and our ability to sell our drugs;

costs involved in establishing manufacturing capabilities for clinical trial and commercial quantities of our drugs;

competing technological and market developments;

market acceptance of our products;

costs for recruiting and retaining management, employees and consultants;

costs for educating physicians regarding the application and use of our products;

whether we are able to maintain our listing on a national exchange;

uncertainty and economic instability resulting from terrorist acts and other acts of violence or war; and

the condition of capital markets and the economy generally, both in the U.S. and globally.

We may consume available resources more rapidly than currently anticipated, resulting in the need for additional funding sooner than expected. We may seek to raise any necessary additional funds through the issuance of warrants, equity or debt financings or executing collaborative arrangements with corporate partners or other sources, which may be dilutive to existing stockholders or have a material effect on our current or future business prospects. In addition, in the event that additional funds are obtained through arrangements with collaborative partners or other sources, we may have to relinquish economic and/or proprietary rights to some of our technologies or products under development that we would otherwise seek to develop or commercialize by ourselves. If we cannot secure adequate financing when needed, we may be required to delay, scale back or eliminate one or more of our research and development programs or to enter into license or other arrangements with third parties to commercialize products or technologies that we would otherwise seek to develop ourselves and commercialize ourselves. In such an event, our business, prospects, financial condition, and results of operations may be adversely affected.

We will require additional funds to conduct research and development, establish and conduct preclinical and clinical trials, establish commercial-scale manufacturing arrangements and provide for the marketing and distribution of our products. Our ability to execute our operating plan depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise.

We have incurred net losses and negative cash flows since inception. We currently have no product revenues, and may not succeed in developing or commercializing any products that will generate product or licensing revenues. We do not expect to have any products on the market for several years. Our primary activity to date has been research and development and conducting clinical trials. Development of our product candidates requires a process of preclinical and clinical testing, during which our product candidates could fail. We may not be able to enter into agreements with one or more companies experienced in the manufacturing and marketing of therapeutic drugs and, to the extent that we are unable to do so, we may not be able to market our product candidates. Whether we achieve profitability or not will depend on our success in developing, manufacturing, and marketing our product candidates. We have experienced net losses and negative cash flows from operating activities since inception and we expect such losses and negative cash flows to continue for the foreseeable future. As of June 30, 2017, we had a stockholders’ equity of approximately $10,865,000. The operating loss for the six months ended June 30, 2017 was approximately $6,029,000, and we may never achieve profitability.

Item 6.

Exhibits

			Incorporation by Reference
Exhibit No.	Description	Filed with this Form 10-Q	Form	Filing Date	Exhibit No.

10.1	Form of Restricted Common Stock Agreement	X

31.1	Certification of chief executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

31.2	Certification of chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

32.1	Certification of chief executive officer and chief financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

101	Interactive Data Files	X

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CELLECTAR BIOSCIENCES, INC.

Date: August 14, 2017	By:	/s/ James Caruso
		James Caruso
		President and Chief Executive Officer

EX-10.1 2 v472296_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

RESTRICTED COMMON STOCK

Granted by

Cellectar Biosciences, Inc. (the “Company”)

Under the 2015 Stock Incentive Plan

This Restricted Common Stock (the “Grant”) is and shall be subject in every respect to the provisions of the Company’s 2015 Stock Incentive Plan, as amended from time to time (the “Plan”), which is incorporated herein by reference and made a part hereof. The holder of this Restricted Common Stock (the “Holder”) hereby accepts this Grant subject to all the terms and provisions of the Plan and agrees that (a) in the event of any conflict between the terms hereof and those of the Plan, the latter shall prevail, and (b) all decisions under and interpretations of the Plan by the Board or the Committee (as each term is defined in the Plan) shall be final, binding and conclusive upon the Holder and his or her heirs and legal representatives.

Name of Holder: _______________.

Date of Grant: _____________ 2017.

Number of Shares Granted: ______________.

(a) Vesting Schedule. This Grant shall vest in three equal annual installments beginning on the first anniversary of the date of grant (each such anniversary shall be considered the “Scheduled Vesting Date” for the installment to which it applies). With respect to each installment, the Holder must be continuously employed with the Company from the date of grant through the Scheduled Vesting Date in order to become vested with respect to such installment.

(b) Accelerated Vesting. Notwithstanding Section 4(a), the unvested portion of the Grant is subject to acceleration and full vesting prior to a Scheduled Vesting Date if there is an Acceleration Event. As used herein, an “Acceleration Event” shall mean either of the following events, but only if such event occurs within one (1) year following, or in connection with but prior to, a Change of Control (as defined in the Plan):

(i) termination by the Company of the Holder’s employment or service relationship with the Company for any reason other than for Cause (as defined in the Plan); or

(ii) the Holder’s resignation as an employee of, or service provider to, the Company, other than for reasons of Disability (as defined in the Plan) following (x) a significant reduction in the nature or scope of the Holder’s duties, responsibilities, authority or powers, from the duties, responsibilities, authority or powers exercised by the Holder immediately prior to the Change of Control, or (y) a reduction in the Holder’s annual base salary (or base fees, as applicable) or benefits as in effect on the date of the Change of Control, except for across-the-board salary or benefits reductions affecting all similarly situated personnel of the Company, or (z) a transfer of the Holder from the office of the Company where he is based immediately before the Change of Control to an office more than twenty-five (25) miles away such office (unless the distance the Holder has to travel to work is actually shortened as a result of such transfer).

For purposes of this Section 4, “Company” shall include any surviving entity, in the case of a merger or acquisition in which the Company is not the surviving entity.

Termination of Employment or Provision of Services for Cause. This Grant shall immediately terminate upon termination of the Holder’s employment with, or provision of services to, the Company by the Company for Cause and all shares subject to the Grant, whether or not vested, shall be immediately forfeit to the Company.

Lock-Up Agreement. The Holder agrees for a period of up to 180 days from the effective date of any registration of securities of the Company under the Securities Act of 1933, as amended (the “Securities Act”), upon request of the Company or underwriters managing any underwritten offering of the Company’s securities, not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any shares issued pursuant to the Grant, without the prior written consent of the Company and such underwriters.

Tax Withholding. The Company’s obligation to deliver shares pursuant to the Grant shall be subject to the Holder’s satisfaction of any federal, state and local income and employment tax withholding requirements. Such withholding tax shall be paid in cash by or on behalf of the Holder.

Notice. Any notice to be given to the Company hereunder shall be deemed sufficient if addressed to the Company and delivered to the office of the Company, 3301 Agriculture Drive, Madison, WI 53716, attention of the president, or such other address as the Company may hereafter designate.

Any notice to be given to the Holder hereunder shall be deemed sufficient if addressed to and delivered in person to the Holder at his or her address furnished to the Company or when deposited in the mail, postage prepaid, addressed to the Holder at such address.

IN WITNESS WHEREOF, the parties have executed this Grant, or caused this Grant to be executed, as of the Date of Grant.

CELLECTAR BIOSCIENCES, INC.

By: ___________________________

Chad Kolean, VP of Finance/CFO

The undersigned Holder hereby acknowledges receipt of a copy of the Plan and this Grant, and agrees to the terms of this Grant and the Plan.

___________________________________

Holder

EX-31.1 3 v472296_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

I, JAMES CARUSO, certify that:

I have reviewed this quarterly report on Form 10-Q of Cellectar Biosciences, Inc., a Delaware Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially effected, or is reasonably likely to materially effect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely effect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2017

/s/ James Caruso
James Caruso
President and Chief Executive Officer (Principal Executive Officer)

EX-31.2 4 v472296_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

I, CHAD KOLEAN, certify that:

I have reviewed this quarterly report on Form 10-Q of Cellectar Biosciences, Inc., a Delaware Corporation;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2017

/s/ Chad Kolean
Chad Kolean
Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 5 v472296_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. § 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Cellectar Biosciences, Inc. (the “Company”) for the quarter ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, James Caruso, President and Chief Executive Officer of the Company, and Chad Kolean, Vice President, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to our knowledge, that:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ James Caruso
James Caruso
President and Chief Executive Officer (Principal Executive Officer)

Date: August 14, 2017

/s/ Chad Kolean
Chad Kolean
Chief Financial Officer (Principal Financial and Accounting Officer)

Date: August 14, 2017

EX-101.INS 6 clrb-20170630.xml XBRL INSTANCE DOCUMENT 0001279704 2016-01-01 2016-06-30 0001279704 2016-01-01 2016-12-31 0001279704 2017-01-01 2017-06-30 0001279704 2016-02-01 2016-02-08 0001279704 2016-02-08 0001279704 2016-03-01 2016-03-04 0001279704 2016-04-01 2016-06-30 0001279704 2017-04-01 2017-06-30 0001279704 2017-06-30 0001279704 2017-08-09 0001279704 2016-12-31 0001279704 2015-12-31 0001279704 2016-06-30 0001279704 clrb:February2013PublicOfferingWarrantsMember 2013-02-28 0001279704 clrb:February2013PublicOfferingWarrantsMember 2014-02-01 2014-02-20 0001279704 clrb:August2014PublicOfferingWarrantsMember 2014-08-31 0001279704 clrb:February2013PublicOfferingWarrantsMember 2016-05-01 2016-05-20 0001279704 clrb:February2013PublicOfferingWarrantsMember us-gaap:FairValueInputsLevel3Member 2016-05-20 0001279704 us-gaap:FairValueInputsLevel1Member clrb:February2013PublicOfferingWarrantsMember 2017-06-30 0001279704 us-gaap:FairValueInputsLevel1Member 2017-06-30 0001279704 us-gaap:FairValueInputsLevel2Member clrb:February2013PublicOfferingWarrantsMember 2017-06-30 0001279704 us-gaap:FairValueInputsLevel2Member 2017-06-30 0001279704 us-gaap:FairValueInputsLevel3Member clrb:February2013PublicOfferingWarrantsMember 2017-06-30 0001279704 us-gaap:FairValueInputsLevel3Member 2017-06-30 0001279704 clrb:February2013PublicOfferingWarrantsMember 2017-06-30 0001279704 us-gaap:FairValueInputsLevel1Member clrb:WarrantTwoMember 2017-06-30 0001279704 us-gaap:FairValueInputsLevel2Member clrb:WarrantTwoMember 2017-06-30 0001279704 us-gaap:FairValueInputsLevel3Member clrb:WarrantTwoMember 2017-06-30 0001279704 clrb:WarrantTwoMember 2017-06-30 0001279704 us-gaap:FairValueInputsLevel1Member clrb:February2013PublicOfferingWarrantsMember 2016-12-31 0001279704 us-gaap:FairValueInputsLevel1Member 2016-12-31 0001279704 us-gaap:FairValueInputsLevel2Member clrb:February2013PublicOfferingWarrantsMember 2016-12-31 0001279704 us-gaap:FairValueInputsLevel2Member 2016-12-31 0001279704 us-gaap:FairValueInputsLevel3Member clrb:February2013PublicOfferingWarrantsMember 2016-12-31 0001279704 us-gaap:FairValueInputsLevel3Member 2016-12-31 0001279704 clrb:February2013PublicOfferingWarrantsMember 2016-12-31 0001279704 us-gaap:FairValueInputsLevel1Member clrb:WarrantTwoMember 2016-12-31 0001279704 us-gaap:FairValueInputsLevel2Member clrb:WarrantTwoMember 2016-12-31 0001279704 us-gaap:FairValueInputsLevel3Member clrb:WarrantTwoMember 2016-12-31 0001279704 clrb:WarrantTwoMember 2016-12-31 0001279704 clrb:TwoThousandThirteenWarrantsMember 2017-01-01 2017-06-30 0001279704 clrb:TwoThousandThirteenWarrantsMember 2016-01-01 2016-12-31 0001279704 us-gaap:WarrantMember 2016-01-01 2016-12-31 0001279704 us-gaap:FairValueInputsLevel3Member 2015-12-31 0001279704 us-gaap:FairValueInputsLevel3Member 2017-01-01 2017-06-30 0001279704 us-gaap:FairValueInputsLevel3Member 2016-01-01 2016-12-31 0001279704 us-gaap:CommonStockMember clrb:LadenburgThalmannMember 2016-11-01 2016-11-23 0001279704 us-gaap:SeriesAPreferredStockMember clrb:LadenburgThalmannMember 2016-11-01 2016-11-23 0001279704 us-gaap:CommonStockMember clrb:LadenburgThalmannMember us-gaap:OverAllotmentOptionMember 2016-11-01 2016-11-23 0001279704 us-gaap:SeriesAPreferredStockMember clrb:LadenburgThalmannMember 2016-11-23 0001279704 clrb:LadenburgThalmannMember 2016-11-23 0001279704 clrb:LadenburgThalmannMember 2016-11-01 2016-11-23 0001279704 clrb:LadenburgThalmannMember us-gaap:OverAllotmentOptionMember 2016-11-01 2016-11-23 0001279704 clrb:SeriesWarrantsMember clrb:LadenburgThalmannMember 2016-11-01 2016-11-23 0001279704 clrb:UnderwrittenOffering2016Member clrb:LadenburgThalmannMember 2016-11-01 2016-11-29 0001279704 us-gaap:SeriesAPreferredStockMember 2016-12-31 0001279704 us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-06-30 0001279704 clrb:SeriesCPreFundedWarrantMember 2017-01-01 2017-06-30 0001279704 clrb:LadenburgThalmannMember 2016-04-01 2016-04-15 0001279704 clrb:SeriesBPreFundedWarrantMember 2016-04-01 2016-04-15 0001279704 clrb:SeriesWarrantsMember 2016-04-15 0001279704 clrb:SeriesZConvertiblePreferredStockMember 2016-04-15 0001279704 us-gaap:OverAllotmentOptionMember clrb:SeriesPrefundedWarrantMember 2016-04-01 2016-04-15 0001279704 clrb:SeriesPrefundedWarrantMember 2016-04-01 2016-04-15 0001279704 clrb:SeriesBPreFundedWarrantMember 2016-04-15 0001279704 clrb:SeriesPrefundedWarrantMember 2016-04-15 0001279704 clrb:UnderwrittenOffering2016Member 2016-04-01 2016-04-20 0001279704 clrb:SeriesBPreFundedWarrantMember 2016-04-01 2016-04-20 0001279704 clrb:SeriesWarrantsMember 2016-04-01 2016-04-20 0001279704 clrb:UnderwrittenOffering2016Member 2016-04-13 0001279704 clrb:November2016PublicOfferingSeriesCMember 2017-06-30 0001279704 clrb:April2016UnderwrittenRegisteredSeriesMember 2017-06-30 0001279704 clrb:October2015IncrementalSeriesMember 2017-06-30 0001279704 clrb:October2015PrivatePlacementSeriesMember 2017-06-30 0001279704 clrb:October2015OfferingPlacementAgentMember 2017-06-30 0001279704 clrb:August2014PublicOfferingMember 2017-06-30 0001279704 clrb:February2013PublicOfferingMember 2017-06-30 0001279704 clrb:February2013PublicOfferingPlacementAgentsMember 2017-06-30 0001279704 clrb:NovemberPrivatePlacementMember 2017-06-30 0001279704 clrb:November2016PublicOfferingSeriesCMember 2017-01-01 2017-06-30 0001279704 clrb:April2016UnderwrittenRegisteredSeriesMember 2017-01-01 2017-06-30 0001279704 clrb:October2015IncrementalSeriesMember 2017-01-01 2017-06-30 0001279704 clrb:October2015PrivatePlacementSeriesMember 2017-01-01 2017-06-30 0001279704 clrb:October2015OfferingPlacementAgentMember 2017-01-01 2017-06-30 0001279704 clrb:August2014PublicOfferingMember 2017-01-01 2017-06-30 0001279704 clrb:February2013PublicOfferingMember 2017-01-01 2017-06-30 0001279704 clrb:February2013PublicOfferingPlacementAgentsMember 2017-01-01 2017-06-30 0001279704 clrb:NovemberPrivatePlacementMember 2017-01-01 2017-06-30 0001279704 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001279704 us-gaap:PreferredStockMember 2017-01-01 2017-06-30 0001279704 us-gaap:PreferredStockMember 2016-01-01 2016-12-31 0001279704 clrb:August2014UnderwrittenOfferingMember 2017-06-30 0001279704 us-gaap:SecuredDebtMember 2017-03-31 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001279704 us-gaap:ResearchAndDevelopmentExpenseMember clrb:NonEmployeeConsultantStockOptionMember 2017-04-01 2017-06-30 0001279704 us-gaap:ResearchAndDevelopmentExpenseMember clrb:NonEmployeeConsultantStockOptionMember 2016-04-01 2016-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0001279704 us-gaap:ResearchAndDevelopmentExpenseMember clrb:NonEmployeeConsultantStockOptionMember 2017-01-01 2017-06-30 0001279704 us-gaap:ResearchAndDevelopmentExpenseMember clrb:NonEmployeeConsultantStockOptionMember 2016-01-01 2016-06-30 0001279704 clrb:EmployeeMember 2017-01-01 2017-06-30 0001279704 us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2017-01-01 2017-06-30 0001279704 us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2016-01-01 2016-06-30 0001279704 us-gaap:SeriesAPreferredStockMember 2017-06-30 0001279704 clrb:TwoThousandFifteenWarrantsMember 2017-01-01 2017-06-30 0001279704 us-gaap:MinimumMember clrb:TwoThousandThirteenWarrantsMember 2016-01-01 2016-12-31 0001279704 us-gaap:MaximumMember clrb:TwoThousandThirteenWarrantsMember 2016-01-01 2016-12-31 0001279704 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001279704 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0001279704 clrb:EmployeeAndDirectorStockOptionMember 2017-04-01 2017-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember 2016-03-31 2016-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember 2017-01-01 2017-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember 2016-01-01 2016-06-30 0001279704 clrb:EmployeeMember 2016-01-01 2016-12-31 0001279704 us-gaap:StockOptionMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001279704 us-gaap:StockOptionMember us-gaap:ConvertibleDebtMember 2016-01-01 2016-06-30 0001279704 us-gaap:EmployeeStockOptionMember 2017-06-30 0001279704 us-gaap:MinimumMember us-gaap:RestrictedStockMember 2017-06-30 0001279704 us-gaap:MaximumMember us-gaap:RestrictedStockMember 2017-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2017-06-30 2017 Q2 Cellectar Biosciences, Inc. 0001279704 --12-31 Smaller Reporting Company CLRB 13922170

8313073

11444619

969585

693569

9337658

12193188

1576244

1444058

1675462

11872

12601236

15324580

86591

1466297

1416433

119600

127125

2877

2727

1588774

1632876

144151

146583

3772

5249

147923

151832

1736697

1784708

875572

135

104

87664282

83451222

-76799878

-70787026

10864539

13539872

12601236

15324580

55000

965184

1367726

2332910

-2332910

198370

1637

-2132903

200007

2175929

1040540

3216469

-3216469

90000

4941

-3121528

94941

2004638

2328981

4333619

-4333619

3023092

2187

-1308340

3025279

4032810

1995896

6028706

-6028706

7525

8328

-6012853

15853

188325

181461

396760

222887

49864

140838

263169

-66999

-5651030

-3719898

320510

4207

-320510

-4207

1327

1191

2839994

7788458

-3131546

4064353

3857791

7922144

364

2753

150633

2432

651

2940759

652516

86591

121330

55000

82500

27500

494315

16250

38750

101000

18600

101000

100000

27125

100000

0.76

0.0121

P7M20D

0.0165

P4Y6M

0.8973

27125 2067000

1392429

-8525

-647446

18600

800000

4533356

66667

1.50

5333356 800000 1.50

66667

100000

9200000

8300000

1133339

1960506 2940759

1378364

1908021 3286385 492957

492957

2.13 2.12

0.01

3.04

1871321

1908021 3779342

8000000

7200000

2.13

40000000

8741536

4172850

3626942

300006

86365

3750

504019

38750

3854

5000

1.5

3.04

2.13

28.3

46.8

1.5

125

250

2021-11-29 2021-04-20 2021-10-20 2021-04-01 2020-10-01 2019-08-20 2018-02-20 2018-02-04 2017-11-02 9760269 12321724 8741536 10716952 0 1133339

9704

450000

40072

191014

13335

106606

231086

119969

56720

340040

24370

198855

-338

0.02

146360

412373

146360

16.31

3.3

16.31

13819

27641

13819

P8Y6M11D

P9Y25D

P8Y6M11D

471433

87300

7.59

1.93

558733

6.7

1740000

408000 736000 72000 2.37 524000

8741536

4629842

-0.23

-0.49

-0.47

-0.50

13461994

4328303

12740149

2617341

0.00001

7000

80000000

13462170

10368325

7371121

0 594 -12847 38569

1392000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Cellectar Biosciences, Inc. (the “Company”) is a biopharmaceutical company developing compounds for the treatment of cancer. The Company’s headquarters are located in Madison, Wisconsin.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company is subject to a number of risks similar to those of other small pharmaceutical companies. Principal among these risks are dependence on key individuals, competition from substitute products and larger companies, the successful development and marketing of its products in a highly regulated environment and the need to obtain additional financing necessary to fund future operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> The accompanying financial statements have been prepared on a basis that assumes the Company will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has devoted substantially all of its efforts toward research and development and has, during the six months ended June 30, 2017, generated an operating loss of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,029,000</font>. The Company expects that it will continue to generate operating losses for the foreseeable future.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company believes that its cash balance at June 30, 2017 is adequate to fund operations at budgeted levels into second quarter 2018. The Company’s ability to execute its operating plan beyond second quarter 2018 depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. The Company plans to continue actively pursuing financing alternatives, but there can be no assurance that it will obtain the necessary funding, raising substantial doubt about the Company’s ability to continue as a going concern within one year of the date these financial statements are issued. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The accompanying condensed consolidated balance sheet as of December 31, 2016 has been derived from audited financial statements. The accompanying unaudited condensed consolidated balance sheet as of June 30, 2017, the condensed consolidated statements of operations for the three months and six months ended June 30, 2017 and 2016, the condensed consolidated statements of cash flows for the six months ended June 30, 2017 and 2016 and the related interim information contained within the notes to the condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions, rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments which are of a nature necessary for the fair presentation of the Company’s consolidated financial position at June 30, 2017 and consolidated results of its operations for the three months and six months ended June 30, 2017 and 2016, and its cash flows for the six months ended June 30, 2017 and 2016. The results for the six months ended June 30, 2017 are not necessarily indicative of future results.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes thereto included in the Company’s Form 10-K for the fiscal year ended December 31, 2016, which was filed with the SEC on March 15, 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Principles of Consolidation</font></i></b> <font style="FONT-SIZE: 10pt">  The consolidated financial statements include the accounts of the Company and the accounts of its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Restricted Cash</i> <i></i></strong> The Company accounts for cash that is restricted for other than current operations as restricted cash. Restricted cash at June 30, 2017 and December 31, 2016 consisted of a certificate of deposit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55,000</font></font> required under the Company’s lease agreement for its Madison, Wisconsin facility.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Goodwill</font></i></b> <font style="FONT-SIZE: 10pt"> Goodwill is not amortized, but is required to be evaluated for impairment annually or whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company evaluates goodwill for impairment annually in the fourth fiscal quarter and additionally on an interim basis if an event occurs or there is a change in circumstances, such as a decline in the Company’s stock price or a material adverse change in the business climate, which would more likely than not reduce the fair value of the reporting unit below its carrying amount. No such event or change in circumstances occurred; therefore no changes in goodwill were made during the six months ended June 30, 2017 and 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill. The standard streamlines the methodology for calculating whether goodwill is impaired based upon whether the carrying amount of goodwill exceeds the reporting unit’s fair value. ASU 2017-04 applies to public business entities and those other entities that have goodwill reported in their financial statements and have not elected the private company alternative for the subsequent measurement of goodwill and is effective for annual and interim reporting periods beginning after December 15, 2019, with early adoption permitted. The Company does not expect that the adoption of this standard will have a material effect on its financial statements.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Impairment of Long</font></i></b><font style="FONT-SIZE: 10pt">-<b><i>Lived Assets</i></b>  Long-lived assets other than goodwill consist primarily of fixed assets, which we periodically evaluate for potential impairment. Whenever events or circumstances change, an assessment is made as to whether there has been an impairment in the value of long-lived assets by determining whether projected undiscounted cash flows generated by the applicable asset exceed its net book value as of the assessment date. No such event or change in circumstances occurred; therefore no such impairment occurred during the six months ended June 30, 2017 and 2016.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Stock-Based Compensation</font></i></b> <font style="FONT-SIZE: 10pt"> The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for awards that are not performance-based is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Awards of stock that are not performance-based are valued at the fair market value on the date of the grant and are amortized over the service period of the award. Non-employee stock-based compensation is accounted for in accordance with the guidance of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) Topic 505, <i> Equity.</i> As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Fair Value of Financial Instruments</font></i></b> <font style="FONT-SIZE: 10pt"> The guidance under FASB ASC Topic 825, <i> Financial Instruments</i>, requires disclosure of the fair value of certain financial instruments. Financial instruments in the accompanying financial statements consist of cash equivalents, accounts payable and long-term obligations. The carrying amount of cash equivalents and accounts payable approximate their fair value due to their short-term nature. The carrying value of remaining long-term obligations, including the current portion, approximates fair value because the fixed interest rate approximates current market interest rates available on similar instruments.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Derivative Instruments</i> <i></i></strong> The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities.  In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain a certain type of cash settlement feature, “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 533,065</font></font> at June 30, 2017 and December 31, 2016. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At June 30, 2017 and December 31, 2016, these warrants represented the only outstanding derivative instruments issued or held by the Company.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Leases</font></i></b> <font style="FONT-SIZE: 10pt"> In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is currently evaluating the method of adoption and the impact of adopting ASU 2016-02 on its results of operations, cash flows and financial position.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Leases</font></i></b> <font style="FONT-SIZE: 10pt"> In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is currently evaluating the method of adoption and the impact of adopting ASU 2016-02 on its results of operations, cash flows and financial position.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

55000

533065

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">2. FAIR VALUE</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In accordance with the Fair Value Measurements and Disclosures Topic of the FASB ASC 820, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> </div> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Symbol"> ·</font></div> </td> <td> <div><font style="FONT-SIZE: 10pt">Level 1: Input prices quoted in an active market for identical financial assets or liabilities.</font></div> </td> </tr> </table> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Symbol"> ·</font></div> </td> <td> <div><font style="FONT-SIZE: 10pt">Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.</font></div> </td> </tr> </table> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Symbol"> ·</font></div> </td> <td> <div><font style="FONT-SIZE: 10pt">Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-SIZE: 10pt">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company issued warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 82,500</font> common shares in a February 2013 public offering (the “February 2013 Public Offering Warrants”). On February 20, 2014, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 27,500</font> of the February 2013 Public Offering Warrants expired. On May 20, 2016, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 16,250</font> warrants were exercised. The remaining <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 38,750</font> warrants are classified within the Level 3 hierarchy.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In August 2014, as part of an underwritten public offering, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 494,315</font> warrants to purchase common stock (the “August 2014 Warrants”). The August 2014 Warrants are listed on the Nasdaq Capital Market under the symbol “CLRBW,” however, there are certain periods where trading volume is low; therefore, they are classified as Level 2 within the hierarchy.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of June 30, 2017 and December 31, 2016:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>June 30, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>February 2013 Public Offering Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>August 2014 Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>101,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>101,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>101,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>18,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>119,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>December 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>February 2013 Public Offering Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>August 2014 Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>27,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>127,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In order to estimate the value of the February 2013 Public Offering Warrants considered to be derivative instruments, the Company uses a modified option-pricing model together with assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rates, volatility, the contractual term of the warrants, future financing requirements and dividend rates. The future financing estimates are based on the Company’s estimates of anticipated cash requirements over the term of the warrants as well as the frequency of required financings based on its assessment of its historical financing trends and anticipated future events. Due to the nature of these inputs and the valuation technique utilized, these warrants are classified within the Level 3 hierarchy.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the modified option-pricing assumptions used:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="69%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Six Months <br/> Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Twelve Months <br/> Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="69%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>June 30, <br/> 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="7%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>December 31, <br/> 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="69%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>76</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>92.72-134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="69%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.53-1.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="69%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1.14-1.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="69%"> <div>Dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">During fiscal year 2016, the Company had warrants outstanding for part of the year that were considered financial instruments. Those warrants were either extinguished or amended such that they were no longer considered financial instruments as of December 31, 2016, and were, therefore, not financial instruments during the three or six months ended June 30, 2017. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the modified option-pricing assumptions used for the period they were considered financial instruments:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="84%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Twelve Months <br/> Ended <br/> December 31, <br/> 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="84%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>89.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="84%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="84%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>4.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="84%"> <div>Dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="69%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Six Months <br/> Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Twelve Months<br/> Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="69%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>June 30, <br/> 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>December 31, <br/> 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="69%"> <div>Beginning balance  Fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>27,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>2,067,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="69%"> <div>Reclassification to equity for warrants that are no longer derivative liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(1,392,429)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="69%"> <div>Gain on derivatives resulting from change in fair value or extinguishment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(8,525)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(647,446)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="69%"> <div>Ending balance  Fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>18,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>27,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In order to estimate the fair value of the August 2014 Warrants, the Company calculated the weighted average closing price for the trailing 10 day period with trades that ended on the balance sheet date.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of June 30, 2017 and December 31, 2016:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>June 30, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>February 2013 Public Offering Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>August 2014 Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>101,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>101,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>101,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>18,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>119,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>December 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>February 2013 Public Offering Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>August 2014 Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>27,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>127,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following table summarizes the modified option-pricing assumptions used: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="69%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Six Months <br/> Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Twelve Months <br/> Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="69%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>June 30, <br/> 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="7%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>December 31, <br/> 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="69%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>76</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>92.72-134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="69%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.53-1.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="69%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1.14-1.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="69%"> <div>Dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following table summarizes the modified option-pricing assumptions used for the period they were considered financial instruments: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="84%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Twelve Months <br/> Ended <br/> December 31, <br/> 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="84%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>89.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="84%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="84%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>4.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="84%"> <div>Dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.9272

1.34

0.0053

0.0115

P1Y1M20D

P1Y10M20D

1-for-10 reverse split

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">5. STOCK-BASED COMPENSATION</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">Accounting for Stock-Based Compensation</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock grants and stock option grants and recorded in connection with stock options granted to non-employee consultants:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Months Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Six Months Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Employee and director stock and stock option grants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">40,072</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">13,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">56,720</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">24,370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">191,014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">106,606</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">340,040</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">198,855</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">231,086</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">119,941</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">396,760</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">223,225</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Non-employee consultant stock option grants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(338)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Total stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">231,086</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">119,969</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">396,760</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">222,887</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">Assumptions Used In Determining Fair Value for Stock Options</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Valuation and amortization method</font></i><font style="FONT-SIZE: 10pt">. The fair value of each stock option award is estimated on the grant date using the Black-Scholes option-pricing model. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. The estimated fair value of the non-employee options is amortized to expense over the period during which a non-employee is required to provide services for the award (usually the vesting period).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Volatility.</font></i> <font style="FONT-SIZE: 10pt">The Company estimates volatility based on an average of (1) the Company’s historical volatility since its common stock has been publicly traded and (2) review of volatility estimates of publicly held drug development companies with similar market capitalizations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Risk-free interest rate</font></i><font style="FONT-SIZE: 10pt">. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Expected term</font></i><font style="FONT-SIZE: 10pt">. The expected term of stock options granted is based on an estimate of when options will be exercised in the future. The Company applied the simplified method of estimating the expected term of the options, as described in the SEC’s Staff Accounting Bulletins 107 and 110, as the historical experience is not indicative of the expected behavior in the future. The expected term, calculated under the simplified method, is applied to groups of stock options that have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. The Company applied the simplified method to non-employees who have a truncation of term based on termination of service and utilizes the contractual life of the stock options granted for those non-employee grants which do not have a truncation of service.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><i> Forfeitures.</i>  The Company records stock-based compensation expense only for those awards that are expected to vest. A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. An annual forfeiture rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font></font>% was applied to all unvested options for the six months ended June 30, 2017 and for the year ended December 31, 2016. Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.</font></div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Exercise prices for all grants made during the six months ended June 30, 2017 and 2016 were equal to the market value of the Company’s common stock on the date of grant.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">Stock Option Activity</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of stock option activity is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number of <br/> Shares Issuable <br/> Upon Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted <br/> Average <br/> Remaining<br/> Contracted </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of Outstanding <br/> Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average <br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Term in<br/> Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic <br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding at December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>471,433</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7.59</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>87,300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding at June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>558,733</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Vested, June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>146,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.53</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,819</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Unvested, June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>412,373</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.07</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>27,641</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Exercisable at June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>146,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.53</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>13,819</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the estimated per-share fair value of common stock at the end of the respective period and the exercise price of the underlying options. There have been no options exercised during 2017. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Stock Grants</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">During the three months ended June 30, 2017, the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 460,000</font> shares of restricted common stock to members of the executive team. The restricted stock was granted at a price of either $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.08</font> or $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.10</font>, which in each case were the closing prices of the stock on the dates of issuance, and vests in equal annual amounts over three years. The related expense will be amortized ratably over the vesting period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> The unvested portion of the restricted stock grants is not considered to be outstanding for accounting purposes; therefore, the related shares are not included in the earnings per share calculation or the shares reported as outstanding on the balance sheet, as of or for the periods ended June 30, 2017. Note that such shares are considered outstanding from a legal perspective as of the date of grant.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Unrecognized Compensation Cost</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of June 30, 2017, there was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,740,000</font> of total unrecognized compensation cost related to unvested stock-based compensation arrangements. Of this total amount, the Company expects to recognize approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">408,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">736,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">524,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">72,000</font> during 2017, 2018, 2019 and 2020 respectively. The Company’s expense estimates are based upon the expectation that all unvested stock grants and stock options will vest in the future, less the forfeiture rate discussed above. The weighted-average grant-date fair value of vested and unvested stock grants and stock options outstanding at June 30, 2017 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12.42</font></font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.37</font>, respectively.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock grants and stock option grants and recorded in connection with stock options granted to non-employee consultants:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Months Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Six Months Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Employee and director stock and stock option grants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">40,072</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">13,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">56,720</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">24,370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">191,014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">106,606</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">340,040</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">198,855</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">231,086</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">119,941</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">396,760</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">223,225</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Non-employee consultant stock option grants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(338)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Total stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">231,086</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">119,969</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">396,760</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">222,887</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">A summary of stock option activity is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number of <br/> Shares Issuable <br/> Upon Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted <br/> Average <br/> Remaining<br/> Contracted </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of Outstanding <br/> Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average <br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Term in<br/> Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic <br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding at December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>471,433</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7.59</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>87,300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding at June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>558,733</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Vested, June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>146,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.53</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,819</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Unvested, June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>412,373</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.07</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>27,641</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Exercisable at June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>146,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.53</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>13,819</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

231086

119941

396760

223225

0.02

460000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">6. INCOME TAXES</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company accounts for income taxes in accordance with the liability method of accounting. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax basis of assets and liabilities, and net operating loss carryforwards (NOLs), using the enacted tax rates. Deferred income tax expense or benefit is based on changes in the asset or liability from period to period. The Company did not record a provision or benefit for federal, state or foreign income taxes for the six months ended June 30, 2017 or 2016 because the Company has experienced losses on a tax basis since inception. Because of the continuing losses and uncertainty associated with the utilization of the NOLs in the future, management has provided a full allowance against the value of its gross deferred tax assets.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company also accounts for the uncertainty in income taxes related to the recognition and measurement of a tax position taken or expected to be taken in an income tax return. The Company follows the applicable accounting guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition related to the uncertainty in income tax positions. No uncertain tax positions have been identified.</div> </div> </div> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1018733

397882

12.42

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><strong><i>Derivative Instruments</i> <i></i></strong> The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities.  In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain a certain type of cash settlement feature, “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 533,065</font></font> at June 30, 2017 and December 31, 2016. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At June 30, 2017 and December 31, 2016, these warrants represented the only outstanding derivative instruments issued or held by the Company.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

2.08

2.10

These warrants have a certain type of cash settlement feature or the exercise price for which the warrant may be exercised is subject to adjustment for “down-rounds” and the warrants have been accounted for as derivative instruments as described in Note 3, with the exception of 9,704 warrants issued in August 2014. Due to the issuance of common stock at $1.50 per share as part of the November 2016 Underwritten Offering, the remaining outstanding warrants issued as part of the February 2013 Public Offering were adjusted to reflect the revised exercise price of $1.50 each.

EX-101.SCH 7 clrb-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - FAIR VALUE link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - NOTES PAYABLE link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - NET LOSS PER SHARE link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Policies) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Details Textual) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - FAIR VALUE (Details) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - FAIR VALUE (Details 1) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - FAIR VALUE (Details 2) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - FAIR VALUE (Details 3) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - FAIR VALUE (Details Textual) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - STOCKHOLDERS' EQUITY (Details Textual) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - NOTES PAYABLE (Details Textual) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - STOCK-BASED COMPENSATION (Details 1) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - STOCK-BASED COMPENSATION (Details Textual) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - NET LOSS PER SHARE (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 clrb-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 clrb-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 clrb-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Legal Entity [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Debt Disclosure [Abstract] Long-term Debt [Text Block] Notes Payable Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Text Block] Earnings Per Share [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Consolidation, Policy [Policy Text Block] Consolidation, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Share-Based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Fair Value Of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Derivatives, Policy [Policy Text Block] Derivatives, Policy [Policy Text Block] Statement Of Financial Position [Abstract] Statement [Table] Scenario [Axis] Scenario, Unspecified [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] CURRENT ASSETS: Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT END OF PERIOD Restricted Cash and Cash Equivalents Restricted cash Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total FIXED ASSETS, NET Fixed assets, net Goodwill GOODWILL Other Assets Noncurrent OTHER ASSETS Liabilities and Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities, Current [Abstract] CURRENT LIABILITIES: Notes Payable, Current, Total Current maturities of notes payable Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued liabilities Derivative Liability, Current Derivative liability Capital Lease Obligations, Current Capital lease obligations, current portion Liabilities, Current, Total Total current liabilities Liabilities Noncurrent [Abstract] LONG-TERM LIABILITIES: Deferred Rent Credit Noncurrent Deferred rent Capital Lease Obligations, Noncurrent Capital lease obligation, less current portion Liabilities, Noncurrent, Total Total long-term liabilities Liabilities, Total TOTAL LIABILITIES Commitments and Contingencies COMMITMENTS AND CONTINGENCIES (Note 8) Stockholders Equity [Abstract] STOCKHOLDERS’ EQUITY: Preferred Stock Value Preferred stock, $0.00001 par value; 7,000 shares authorized; none and 17 Series A issued and outstanding as of June 30, 2017 and December 31, 2016, respectively Common Stock, Value, Issued Common stock, $0.00001 par value; 80,000,000 shares authorized; 13,462,170 and 10,368,325 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively Additional Paid in Capital, Total Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders Equity Attributable to Parent, Total Total stockholders’ equity BALANCE BALANCE Liabilities and Equity, Total TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Fair Value Disclosures [Abstract] Fair Value, Liabilities Measured On Recurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Equity [Abstract] Schedule Of Stockholders' Equity Note, Warrants Or Rights [Table Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule Of Compensation Cost For Share-Based Payment Arrangements, Allocation Of Share-Based Compensation Costs By Plan [Table Text Block] Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Private Placement [Axis] Net Income (Loss) Attributable to Parent, Total Net Income (Loss) Attributable to Parent, Total NET LOSS Net loss Net loss Certificates of Deposit, at Carrying Value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Equity Components [Axis] Equity Component [Domain] February 2013 Public Offering Warrants [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Liabilities [Abstract] Liabilities: Range [Axis] Range [Domain] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) Class of Warrant or Right [Table] November 2016 Public Offering Series C [Member] April 2016 Underwritten Registered Series A [Member] October 2015 Incremental Series A [Member] October 2015 Private Placement Series A [Member] October 2015 Offering - Placement Agent [Member] August 2014 Public Offering [Member] February 2013 Public Offering [Member] Consolidation Items [Axis] Consolidation Items [Domain] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Domain] Debt Instrument [Axis] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise Price (in dollars per share) Warrants Expiration Date Warrants Expiration Date Expiry date of warrants held. Class of Stock [Axis] Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, issued Preferred Stock Shares Outstanding Preferred stock, outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock [Member] Debt Instrument, Name [Domain] Affiliation with Entity [Axis] Property, Casualty Insurance Underwriters, Affiliation with Registrant [Domain] Stock Issued During Period, Shares, New Issues Issuance of common stock and warrants, net of issuance costs (in shares) Line of Credit Facility [Table] Credit Facility [Axis] Credit Facility [Domain] Secured Debt [Member] Department [Axis] Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table] Option Indexed to Issuers Equity, Type [Axis] Option Indexed to Issuers Equity, Type [Domain] Employee and Director Stock Option [Member] Employee and Director Stock Option Grants [Member] Employee and director stock option member Non Employee Consultant Stock Option [Member] Non Employee Consultant Stock Option Grants [Member] Non-Employee Consultant Stock Option Grants [Member]. Income Statement Location [Axis] Income Statement Location [Domain] Research and Development Expense [Member] Research and development [Member] General and Administrative Expense [Member] General and administrative [Member] Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items] Share-based Compensation, Total Total stock-based compensation Stock-based compensation expense Schedule of Share-based Compensation, Stock Options, Activity [Table] Share-based Compensation, Stock Options, Activity [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Granted - Number of Shares Issuable Upon Exercise of Outstanding Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Expired- Number of Shares Issuable Upon Exercise of Outstanding Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period Forfeited - Number of Shares Issuable Upon Exercise of Outstanding Options Share Based Compensation Arrangement By Share Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Number Vested - Number of Shares Issuable Upon Exercise of Outstanding Options Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Unvested Outstanding Number Unvested - Number of Shares Issuable Upon Exercise of Outstanding Options The number of unvested equity-based payment instruments, including stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercisable, Number Exercisable - Number of Shares Issuable Upon Exercise of Outstanding Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Outstanding - Weighted Average Exercise Price (in dollars per share) Outstanding - Weighted Average Exercise Price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average exercise price Granted - Weighted Average Exercise Price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Expired- Weighted Average Exercise Price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited - Weighted Average Exercise Price (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award, Options, Vested and Expected To Vest, Exercisable, Weighted Average Exercise Price Vested - Weighted Average Exercise Price (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Exercisable Weighted Average Exercise Price Unvested - Weighted Average Exercise Price (in dollars per share) As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are non vested. Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable - Weighted Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term Vested - Weighted Average Remaining Contracted Term in Years Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term Unvested - Weighted Average Remaining Contracted Term in Years Weighted average of the remaining contractual term for unvested portions of options outstanding and currently exercised or convertible in the 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Minimum [Member] Maximum [Member] Title of Individual [Axis] Relationship to Entity [Domain] Employee [Member] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Award Type [Axis] Equity Award [Domain] Option Indexed to Issuers Equity [Axis] Employee Stock Option [Member] Stock options [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Employee Service Share Based Compensation Nonvested Total Compensation In Current Year Employee Service Share Based Compensation Nonvested Total Compensation In Current Year Aggregate value for unrecognized compensation cost related to the unvested stock-based compensation arrangements in current year. Employee Service Share Based Compensation Nonvested Total Compensation In Year Two Aggregate value for unrecognized compensation cost related to the unvested stock-based compensation arrangements in year two. Employee Service Share Based Compensation Nonvested Total Compensation In Year Three Employee Service Share Based Compensation Nonvested Total Compensation In Year Three Aggregate value for unrecognized compensation cost related to the unvested stock-based compensation arrangements in year three. Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested and Expected To Vest Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award Options Unvested and Expected To Vest Outstanding Number (in shares) Number of outstanding options Unvested and expected to vest held by the Employee Stock Option Plan as of the balance sheet date. Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Warrants [Member] Equity Option [Member] Stock options [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Convertible Debt [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Income Statement [Abstract] Operating Costs and Expenses [Abstract] COSTS AND EXPENSES: Research and Development Expense, Total Research and development General and Administrative Expense, Total General and administrative Costs and Expenses, Total Total costs and expenses Operating Income (Loss), Total LOSS FROM OPERATIONS EX-101.PRE 11 clrb-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2017	Aug. 09, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Entity Registrant Name	Cellectar Biosciences, Inc.
Entity Central Index Key	0001279704
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CLRB
Entity Common Stock, Shares Outstanding		13,922,170

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 8,313,073	$ 11,444,619
Restricted cash	55,000	55,000
Prepaid expenses and other current assets	969,585	693,569
Total current assets	9,337,658	12,193,188
FIXED ASSETS, NET	1,576,244	1,444,058
GOODWILL	1,675,462	1,675,462
OTHER ASSETS	11,872	11,872
TOTAL ASSETS	12,601,236	15,324,580
CURRENT LIABILITIES:
Current maturities of notes payable	0	86,591
Accounts payable and accrued liabilities	1,466,297	1,416,433
Derivative liability	119,600	127,125
Capital lease obligations, current portion	2,877	2,727
Total current liabilities	1,588,774	1,632,876
LONG-TERM LIABILITIES:
Deferred rent	144,151	146,583
Capital lease obligation, less current portion	3,772	5,249
Total long-term liabilities	147,923	151,832
TOTAL LIABILITIES	1,736,697	1,784,708
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.00001 par value; 7,000 shares authorized; none and 17 Series A issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	0	875,572
Common stock, $0.00001 par value; 80,000,000 shares authorized; 13,462,170 and 10,368,325 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	135	104
Additional paid-in capital	87,664,282	83,451,222
Accumulated deficit	(76,799,878)	(70,787,026)
Total stockholders’ equity	10,864,539	13,539,872
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 12,601,236	$ 15,324,580

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	7,000	7,000
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	13,462,170	10,368,325
Common stock, shares outstanding	13,462,170	10,368,325
Series A Preferred Stock [Member]
Preferred stock, issued	0	17
Preferred stock, outstanding	0	17

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
COSTS AND EXPENSES:
Research and development	$ 2,175,929	$ 965,184	$ 4,032,810	$ 2,004,638
General and administrative	1,040,540	1,367,726	1,995,896	2,328,981
Total costs and expenses	3,216,469	2,332,910	6,028,706	4,333,619
LOSS FROM OPERATIONS	(3,216,469)	(2,332,910)	(6,028,706)	(4,333,619)
OTHER INCOME:
Gain on revaluation of derivative warrants	90,000	198,370	7,525	3,023,092
Interest income, net	4,941	1,637	8,328	2,187
Total other income, net	94,941	200,007	15,853	3,025,279
NET LOSS	$ (3,121,528)	$ (2,132,903)	$ (6,012,853)	$ (1,308,340)
BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share)	$ (0.23)	$ (0.49)	$ (0.47)	$ (0.50)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE (in shares)	13,461,994	4,328,303	12,740,149	2,617,341

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,012,853)	$ (1,308,340)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	188,325	181,461
Stock-based compensation expense	396,760	222,887
Gain on revaluation of derivative warrants	(7,525)	(3,023,092)
Changes in:
Accounts payable and accrued liabilities	49,864	140,838
Prepaid expenses and other current assets	(263,169)	66,999
Other assets and liabilities	(2,432)	(651)
Cash used in operating activities	(5,651,030)	(3,719,898)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of fixed assets	(320,510)	(4,207)
Cash used in investing activities	(320,510)	(4,207)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on notes payable	(86,591)	(121,330)
Proceeds from issuance of common stock, net of underwriting issuance costs	0	7,371,121
Cash paid for issuance costs	0	(150,633)
Proceeds from exercise of warrants	2,940,759	652,516
Cash paid for reverse stock split fractional shares	0	(594)
Change in deferred issuance costs	(12,847)	38,569
Payments on capital lease obligations	(1,327)	(1,191)
Cash provided by financing activities	2,839,994	7,788,458
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(3,131,546)	4,064,353
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	11,444,619	3,857,791
CASH AND CASH EQUIVALENTS AT END OF PERIOD	8,313,073	7,922,144
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest expense	364	2,753
Reclassification to equity for warrants that are no longer derivative instruments	$ 0	$ 1,392,000

XML 17 R6.htm IDEA: XBRL DOCUMENT

NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature Of Business Organization and Going Concern Disclosure [Text Block]

1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN

Cellectar Biosciences, Inc. (the “Company”) is a biopharmaceutical company developing compounds for the treatment of cancer. The Company’s headquarters are located in Madison, Wisconsin.

Restricted Cash — The Company accounts for cash that is restricted for other than current operations as restricted cash. Restricted cash at June 30, 2017 and December 31, 2016 consisted of a certificate of deposit of $55,000 required under the Company’s lease agreement for its Madison, Wisconsin facility.

Derivative Instruments — The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain a certain type of cash settlement feature, “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was 533,065 at June 30, 2017 and December 31, 2016. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At June 30, 2017 and December 31, 2016, these warrants represented the only outstanding derivative instruments issued or held by the Company.

XML 18 R7.htm IDEA: XBRL DOCUMENT

FAIR VALUE

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

2. FAIR VALUE

Level 1: Input prices quoted in an active market for identical financial assets or liabilities.

Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.

	June 30, 2017
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	18,600	$	18,600
August 2014 Warrants		—		101,000		—		101,000
Total	$	—	$	101,000	$	18,600	$	119,600

	December 31, 2016
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	27,125	$	27,125
August 2014 Warrants		—		100,000		—		100,000
Total	$	—	$	100,000	$	27,125	$	127,125

The following table summarizes the modified option-pricing assumptions used:

	Six Months Ended			Twelve Months Ended
	June 30, 2017			December 31, 2016
Volatility		76	%		92.72-134	%
Risk-free interest rate		1.21	%		0.53-1.15	%
Expected life (years)		0.64			1.14-1.89
Dividend		0	%		0	%

	Twelve Months Ended December 31, 2016
Volatility		89.73	%
Risk-free interest rate		1.65	%
Expected life (years)		4.50
Dividend		0	%

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy:

	Six Months Ended		Twelve Months Ended
	June 30, 2017		December 31, 2016
Beginning balance – Fair value	$	27,125	$	2,067,000
Reclassification to equity for warrants that are no longer derivative liabilities		—		(1,392,429)
Gain on derivatives resulting from change in fair value or extinguishment		(8,525)		(647,446)
Ending balance – Fair value	$	18,600	$	27,125

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 19 R8.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

3. STOCKHOLDERS’ EQUITY

November 2016 Underwritten Offering

As of December 31, 2016, 17 shares of Series A preferred stock were outstanding. During the six months ended June 30, 2017, all 17 shares were converted into 1,133,339 shares of common stock.

During the six months ended June 30, 2017, Series C warrants representing 1,960,506 shares of common stock were exercised by the holders, for proceeds of $2,940,759.

April 2016 Underwritten Offering

Warrant Restructuring

2016 Reverse Stock Split and Recapitalization

Common Stock Warrants

The following table summarizes information with regard to outstanding warrants to purchase common stock as of June 30, 2017:

	Number of Shares Issuable Upon Exercise of		Exercise
Offering	Outstanding Warrants		Price			Expiration Date
November 2016 Public Offering Series C		4,172,850	$	1.50		November 29, 2021
April 2016 Underwritten Registered Series A		3,626,942	$	3.04		April 20,2021
October 2015 Incremental Series A		300,006	$	2.13		October 20,2021
October 2015 Private Placement Series A		86,365	$	2.13		April 1, 2021
October 2015 Offering – Placement Agent		3,750	$	28.30		October 1, 2020
August 2014 Public Offering ⁽¹⁾		504,019	$	46.80		August 20, 2019
February 2013 Public Offering ⁽¹⁾		38,750	$	1.50	⁽²⁾	February 20, 2018
February 2013 Public Offering – Placement Agents		3,854	$	125.00		February 4, 2018
November 2012 Private Placement		5,000	$	250.00		November 2, 2017
Total		8,741,536

(1)

(2)

Reserved Shares

The following shares were reserved for future issuance upon exercise of stock options and grants, preferred stock conversions and warrants:

	June 30, 2017		December 31, 2016

Warrants		8,741,536		10,716,952
Preferred stock		—		1,133,339
Stock options and grants		1,018,733		471,433
Total number of shares reserved for future issuance		9,760,269		12,321,724

XML 20 R9.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Notes Payable Disclosure [Text Block]

4. NOTES PAYABLE

XML 21 R10.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

5. STOCK-BASED COMPENSATION

Accounting for Stock-Based Compensation

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Employee and director stock and stock option grants:
Research and development	$	40,072	$	13,335	$	56,720	$	24,370
General and administrative		191,014		106,606		340,040		198,855
		231,086		119,941		396,760		223,225

Non-employee consultant stock option grants:
Research and development		—		28		—		(338)

Total stock-based compensation	$	231,086	$	119,969	$	396,760	$	222,887

Assumptions Used In Determining Fair Value for Stock Options

Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.

Exercise prices for all grants made during the six months ended June 30, 2017 and 2016 were equal to the market value of the Company’s common stock on the date of grant.

Stock Option Activity

A summary of stock option activity is as follows:

	Number of Shares Issuable Upon Exercise		Weighted		Weighted Average Remaining Contracted		Aggregate
	of Outstanding Options		Average Exercise Price		Term in Years		Intrinsic Value
Outstanding at December 31, 2016		471,433	$	7.59
Granted		87,300	$	1.93
Expired		—	$	—
Forfeited		—	$	—
Outstanding at June 30, 2017		558,733	$	6.70

Vested, June 30, 2017		146,360	$	16.31		8.53	$	13,819
Unvested, June 30, 2017		412,373	$	3.30		9.07	$	27,641
Exercisable at June 30, 2017		146,360	$	16.31		8.53	$	13,819

Stock Grants

Unrecognized Compensation Cost

XML 22 R11.htm IDEA: XBRL DOCUMENT

INCOME TAXES

6 Months Ended

Jun. 30, 2017

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

6. INCOME TAXES

XML 23 R12.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

7. NET LOSS PER SHARE

The following potentially dilutive securities have been excluded from the computation of diluted net loss per share since their inclusion would be antidilutive:

	Six Months Ended June 30,
	2017		2016
Warrants		8,741,536		4,629,842
Stock options and grants		1,018,733		397,882

XML 24 R13.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

8. COMMITMENTS AND CONTINGENCIES

XML 25 R14.htm IDEA: XBRL DOCUMENT

NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Policies)

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Consolidation, Policy [Policy Text Block]

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Fair Value of Financial Instruments, Policy [Policy Text Block]

Derivatives, Policy [Policy Text Block]

Lessee, Leases [Policy Text Block]

XML 26 R15.htm IDEA: XBRL DOCUMENT

FAIR VALUE (Tables)

6 Months Ended

Jun. 30, 2017

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

	June 30, 2017
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	18,600	$	18,600
August 2014 Warrants		—		101,000		—		101,000
Total	$	—	$	101,000	$	18,600	$	119,600

	December 31, 2016
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	27,125	$	27,125
August 2014 Warrants		—		100,000		—		100,000
Total	$	—	$	100,000	$	27,125	$	127,125

Schedule Of Changes In Fair Value Warrants Classified Level Three [Table Text Block]

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy:

	Six Months Ended		Twelve Months Ended
	June 30, 2017		December 31, 2016
Beginning balance – Fair value	$	27,125	$	2,067,000
Reclassification to equity for warrants that are no longer derivative liabilities		—		(1,392,429)
Gain on derivatives resulting from change in fair value or extinguishment		(8,525)		(647,446)
Ending balance – Fair value	$	18,600	$	27,125

2013 Warrants [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

The following table summarizes the modified option-pricing assumptions used:

	Six Months Ended			Twelve Months Ended
	June 30, 2017			December 31, 2016
Volatility		76	%		92.72-134	%
Risk-free interest rate		1.21	%		0.53-1.15	%
Expected life (years)		0.64			1.14-1.89
Dividend		0	%		0	%

2015 Warrants [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

The following table summarizes the modified option-pricing assumptions used for the period they were considered financial instruments:

	Twelve Months Ended December 31, 2016
Volatility		89.73	%
Risk-free interest rate		1.65	%
Expected life (years)		4.50
Dividend		0	%

XML 27 R16.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

The following table summarizes information with regard to outstanding warrants to purchase common stock as of June 30, 2017:

	Number of Shares Issuable Upon Exercise of		Exercise
Offering	Outstanding Warrants		Price			Expiration Date
November 2016 Public Offering Series C		4,172,850	$	1.50		November 29, 2021
April 2016 Underwritten Registered Series A		3,626,942	$	3.04		April 20,2021
October 2015 Incremental Series A		300,006	$	2.13		October 20,2021
October 2015 Private Placement Series A		86,365	$	2.13		April 1, 2021
October 2015 Offering – Placement Agent		3,750	$	28.30		October 1, 2020
August 2014 Public Offering ⁽¹⁾		504,019	$	46.80		August 20, 2019
February 2013 Public Offering ⁽¹⁾		38,750	$	1.50	⁽²⁾	February 20, 2018
February 2013 Public Offering – Placement Agents		3,854	$	125.00		February 4, 2018
November 2012 Private Placement		5,000	$	250.00		November 2, 2017
Total		8,741,536

(1)

(2)

Reserved For Future Issuance Upon Exercise Of Stock Options And Warrants Or Conversion Of Debt Text Block [Table Text Block]

The following shares were reserved for future issuance upon exercise of stock options and grants, preferred stock conversions and warrants:

	June 30, 2017		December 31, 2016

Warrants		8,741,536		10,716,952
Preferred stock		—		1,133,339
Stock options and grants		1,018,733		471,433
Total number of shares reserved for future issuance		9,760,269		12,321,724

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Employee and director stock and stock option grants:
Research and development	$	40,072	$	13,335	$	56,720	$	24,370
General and administrative		191,014		106,606		340,040		198,855
		231,086		119,941		396,760		223,225

Non-employee consultant stock option grants:
Research and development		—		28		—		(338)

Total stock-based compensation	$	231,086	$	119,969	$	396,760	$	222,887

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of stock option activity is as follows:

	Number of Shares Issuable Upon Exercise		Weighted		Weighted Average Remaining Contracted		Aggregate
	of Outstanding Options		Average Exercise Price		Term in Years		Intrinsic Value
Outstanding at December 31, 2016		471,433	$	7.59
Granted		87,300	$	1.93
Expired		—	$	—
Forfeited		—	$	—
Outstanding at June 30, 2017		558,733	$	6.70

Vested, June 30, 2017		146,360	$	16.31		8.53	$	13,819
Unvested, June 30, 2017		412,373	$	3.30		9.07	$	27,641
Exercisable at June 30, 2017		146,360	$	16.31		8.53	$	13,819

XML 29 R18.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following potentially dilutive securities have been excluded from the computation of diluted net loss per share since their inclusion would be antidilutive:

	Six Months Ended June 30,
	2017		2016
Warrants		8,741,536		4,629,842
Stock options and grants		1,018,733		397,882

XML 30 R19.htm IDEA: XBRL DOCUMENT

NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Net Income (Loss) Attributable to Parent, Total	$ 3,121,528	$ 2,132,903	$ 6,012,853	$ 1,308,340
Certificates of Deposit, at Carrying Value	$ 55,000		$ 55,000		$ 55,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	533,065		533,065		533,065

XML 31 R20.htm IDEA: XBRL DOCUMENT

FAIR VALUE (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Liabilities:
Derivative Liability, Current	$ 119,600	$ 127,125
February 2013 Public Offering Warrants [Member]
Liabilities:
Derivative Liability, Current	18,600	27,125
August 2014 Warrants [Member]
Liabilities:
Derivative Liability, Current	101,000	100,000
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Derivative Liability, Current	0	0
Fair Value, Inputs, Level 1 [Member] \| February 2013 Public Offering Warrants [Member]
Liabilities:
Derivative Liability, Current	0	0
Fair Value, Inputs, Level 1 [Member] \| August 2014 Warrants [Member]
Liabilities:
Derivative Liability, Current	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Derivative Liability, Current	101,000	100,000
Fair Value, Inputs, Level 2 [Member] \| February 2013 Public Offering Warrants [Member]
Liabilities:
Derivative Liability, Current	0	0
Fair Value, Inputs, Level 2 [Member] \| August 2014 Warrants [Member]
Liabilities:
Derivative Liability, Current	101,000	100,000
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Derivative Liability, Current	18,600	27,125
Fair Value, Inputs, Level 3 [Member] \| February 2013 Public Offering Warrants [Member]
Liabilities:
Derivative Liability, Current	18,600	27,125
Fair Value, Inputs, Level 3 [Member] \| August 2014 Warrants [Member]
Liabilities:
Derivative Liability, Current	$ 0	$ 0

XML 32 R21.htm IDEA: XBRL DOCUMENT

FAIR VALUE (Details 1) - 2013 Warrants [Member]	6 Months Ended	12 Months Ended
FAIR VALUE (Details 1) - 2013 Warrants [Member]	Jun. 30, 2017	Dec. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	76.00%
Risk-free interest rate	1.21%
Expected life (years)	7 months 20 days
Dividend	0.00%	0.00%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility		92.72%
Risk-free interest rate		0.53%
Expected life (years)		1 year 1 month 20 days
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility		134.00%
Risk-free interest rate		1.15%
Expected life (years)		1 year 10 months 20 days

XML 33 R22.htm IDEA: XBRL DOCUMENT

FAIR VALUE (Details 2) - Warrant [Member]	12 Months Ended
FAIR VALUE (Details 2) - Warrant [Member]	Dec. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	89.73%
Risk-free interest rate	1.65%
Expected life (years)	4 years 6 months
Dividend	0.00%

XML 34 R23.htm IDEA: XBRL DOCUMENT

FAIR VALUE (Details 3) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
FAIR VALUE (Details 3) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Reclassification to equity for warrants that are no longer derivative liabilities			$ 0	$ (1,392,000)
Gain on derivatives resulting from change in fair value or extinguishment	$ 90,000	$ 198,370	7,525	3,023,092
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance - Fair value			27,125	$ 2,067,000	$ 2,067,000
Reclassification to equity for warrants that are no longer derivative liabilities			0		(1,392,429)
Gain on derivatives resulting from change in fair value or extinguishment			(8,525)		(647,446)
Ending balance - Fair value	$ 18,600		$ 18,600		$ 27,125

XML 35 R24.htm IDEA: XBRL DOCUMENT

FAIR VALUE (Details Textual) - shares	1 Months Ended
FAIR VALUE (Details Textual) - shares	May 20, 2016	Feb. 20, 2014	Jun. 30, 2017	Aug. 31, 2014	Feb. 28, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			8,741,536
February 2013 Public Offering Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					82,500
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations		27,500
Number Of Warrants Exercised	16,250
February 2013 Public Offering Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Outstanding	38,750
August 2014 Public Offering Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				494,315

XML 36 R25.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details)

6 Months Ended

Jun. 30, 2017

$ / shares

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

8,741,536

November 2016 Public Offering Series C [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

4,172,850

Exercise Price (in dollars per share) | $ / shares

$ 1.5

Warrants Expiration Date

Nov. 29, 2021

April 2016 Underwritten Registered Series A [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

3,626,942

Exercise Price (in dollars per share) | $ / shares

$ 3.04

Warrants Expiration Date

Apr. 20, 2021

October 2015 Incremental Series A [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

300,006

Exercise Price (in dollars per share) | $ / shares

$ 2.13

Warrants Expiration Date

Oct. 20, 2021

October 2015 Private Placement Series A [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

86,365

Exercise Price (in dollars per share) | $ / shares

$ 2.13

Warrants Expiration Date

Apr. 01, 2021

October 2015 Offering - Placement Agent [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

3,750

Exercise Price (in dollars per share) | $ / shares

$ 28.3

Warrants Expiration Date

Oct. 01, 2020

August 2014 Public Offering [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

504,019

^[1]

Exercise Price (in dollars per share) | $ / shares

$ 46.8

^[1]

Warrants Expiration Date

Aug. 20, 2019

^[1]

February 2013 Public Offering [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

38,750

^[1]

Exercise Price (in dollars per share) | $ / shares

$ 1.5

^[1],[2]

Warrants Expiration Date

Feb. 20, 2018

^[1]

February 2013 Public Offering - Placement Agents [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

3,854

Exercise Price (in dollars per share) | $ / shares

$ 125

Warrants Expiration Date

Feb. 04, 2018

November 2012 Private Placement [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

5,000

Exercise Price (in dollars per share) | $ / shares

$ 250

Warrants Expiration Date

Nov. 02, 2017

[1]	These warrants have a certain type of cash settlement feature or the exercise price for which the warrant may be exercised is subject to adjustment for “down-rounds” and the warrants have been accounted for as derivative instruments as described in Note 3, with the exception of 9,704 warrants issued in August 2014.
[2]	Due to the issuance of common stock at $1.50 per share as part of the November 2016 Underwritten Offering, the remaining outstanding warrants issued as part of the February 2013 Public Offering were adjusted to reflect the revised exercise price of $1.50 each.

XML 37 R26.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 1) - shares	6 Months Ended	12 Months Ended
STOCKHOLDERS' EQUITY (Details 1) - shares	Jun. 30, 2017	Dec. 31, 2016
Number Of Shares Reserved For Future Issuance	9,760,269	12,321,724
Preferred Stock [Member]
Number Of Shares Reserved For Future Issuance	0	1,133,339
Warrant [Member]
Number Of Shares Reserved For Future Issuance	8,741,536	10,716,952
Stock options [Member]
Number Of Shares Reserved For Future Issuance	1,018,733	471,433

XML 38 R27.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Textual) - USD ($)			1 Months Ended				6 Months Ended
STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	Mar. 04, 2016	Feb. 08, 2016	Nov. 29, 2016	Nov. 23, 2016	Apr. 20, 2016	Apr. 15, 2016	Jun. 30, 2017	Dec. 31, 2016	Apr. 13, 2016
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							8,741,536
Common Stock, Shares Authorized		40,000,000					80,000,000	80,000,000
Stockholders' Equity, Reverse Stock Split	1-for-10 reverse split	At a special meeting held on February 8, 2016, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to effect a reverse split of the Company’s common stock at a ratio between 1:5 to 1:10 in order to ensure that adequate authorized but unissued shares would be available for anticipated future financings, and to satisfy requirements for the continued listing of the Company’s common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue remained unchanged at 40,000,000. The Company’s stockholders further authorized the board of directors to determine the ratio at which the reverse split would be effected by filing an appropriate amendment to the Company’s certificate of incorporation. The board of directors authorized the ratio of the reverse split and corresponding reduction in authorized shares on February 24, 2016, and effective at the close of business on March 4, 2016, the Company’s certificate of incorporation was amended to effect a 1-for-10 reverse split of the Company’s common stock (the “2016 Reverse Split”). All share and per share numbers included in these consolidated financial statements give effect to the 2016 Reverse Split.
Series A Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Conversion of Stock, Shares Issued							1,133,339
Preferred Stock Shares Outstanding							0	17
Series B Pre-Funded Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.01
Warrants Issued To Purchase Common Stock, Shares					1,908,021	1,908,021
Public Offering Price Per Share Of Shares And Warrants						$ 2.12
Series A Pre-Funded Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding						3.04
Public Offering Price Per Share Of Shares And Warrants						$ 2.13
Series Z Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Warrants Issued To Purchase Common Stock, Shares						492,957
Series C Pre Funded Warrant [Member]
Class of Warrant or Right [Line Items]
Net Proceeds From Offering							$ 2,940,759
Warrants Issued To Purchase Common Stock, Shares							1,960,506
Underwritten Offering 2016 [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues					1,871,321
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 2.13
Stock Issued During Period, Value, New Issues					$ 8,000,000
Proceeds from Issuance Initial Public Offering					$ 7,200,000
Ladenburg Thalmann [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues						1,378,364
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1.50
Warrants Issued To Purchase Common Stock, Shares				5,333,356
Public Offering Price Per Share Of Shares And Warrants				$ 100,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				66,667
Ladenburg Thalmann [Member] \| Series A Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues				68
Convertible Preferred Stock, Shares Issued upon Conversion				4,533,356
Number Of Securities Each Preferred Stock Converted				66,667
Ladenburg Thalmann [Member] \| Underwritten Offering 2016 [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Value, New Issues			$ 9,200,000
Proceeds from Issuance Initial Public Offering			$ 8,300,000
Over-Allotment Option [Member] \| Series A Pre-Funded Warrant [Member]
Class of Warrant or Right [Line Items]
Conversion of Stock, Shares Issued						492,957
Over-Allotment Option [Member] \| Ladenburg Thalmann [Member]
Class of Warrant or Right [Line Items]
Warrants Issued To Purchase Common Stock, Shares				800,000
August 2014 Underwritten Offering [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							9,704
Common Stock [Member] \| Ladenburg Thalmann [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues				800,000
Common Stock [Member] \| Over-Allotment Option [Member] \| Ladenburg Thalmann [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues				800,000
Series A Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants Issued To Purchase Common Stock, Shares						3,286,385
Warrants Issued To Purchase Common Stock, Shares					3,779,342
Series A Warrants [Member] \| Ladenburg Thalmann [Member]
Class of Warrant or Right [Line Items]
Public Offering Price Per Share Of Shares And Warrants				$ 1.50

XML 39 R28.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Textual)	Mar. 31, 2017 USD ($)
Secured Debt [Member]
Line of Credit Facility [Line Items]
Notes Payable, Noncurrent	$ 450,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details) - USD ($)	3 Months Ended			6 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 231,086		$ 119,969	$ 396,760	$ 222,887
Employee and Director Stock Option Grants [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	231,086	$ 119,941		396,760	223,225
Employee and Director Stock Option Grants [Member] \| Research and development [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	40,072		13,335	56,720	24,370
Employee and Director Stock Option Grants [Member] \| General and administrative [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	191,014		106,606	340,040	198,855
Non Employee Consultant Stock Option Grants [Member] \| Research and development [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 0		$ 28	$ 0	$ (338)

XML 41 R30.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 1)	6 Months Ended
STOCK-BASED COMPENSATION (Details 1)	Jun. 30, 2017 USD ($) $ / shares shares
Share-based Compensation, Stock Options, Activity [Line Items]
Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	471,433
Granted - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	87,300
Expired- Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	0
Forfeited - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	0
Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	558,733
Vested - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	146,360
Unvested - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	412,373
Exercisable - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	146,360
Outstanding - Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 7.59
Granted - Weighted Average Exercise Price (in dollars per share) \| $ / shares	1.93
Expired- Weighted Average Exercise Price (in dollars per share) \| $ / shares	0
Forfeited - Weighted Average Exercise Price (in dollars per share) \| $ / shares	0
Outstanding - Weighted Average Exercise Price (in dollars per share) \| $ / shares	6.7
Vested - Weighted Average Exercise Price (in dollars per share) \| $ / shares	16.31
Unvested - Weighted Average Exercise Price (in dollars per share) \| $ / shares	3.3
Exercisable - Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 16.31
Vested - Weighted Average Remaining Contracted Term in Years	8 years 6 months 11 days
Unvested - Weighted Average Remaining Contracted Term in Years	9 years 25 days
Exercisable - Weighted Average Remaining Contracted Term in Years	8 years 6 months 11 days
Vested - Aggregate Intrinsic Value (in dollars) \| $	$ 13,819
Unvested - Aggregate Intrinsic Value (in dollars) \| $	27,641
Exercisable - Aggregate Intrinsic Value (in dollars) \| $	$ 13,819

XML 42 R31.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details Textual) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
STOCK-BASED COMPENSATION (Details Textual) - USD ($)	Jun. 30, 2017	Jun. 30, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share Based Compensation Nonvested Total Compensation In Current Year		$ 408,000
Employee Service Share Based Compensation Nonvested Total Compensation In Year Two		736,000
Employee Service Share Based Compensation Nonvested Total Compensation In Year Three		$ 524,000
Share Based Compensation Arrangement By Share Based Payment Award Options Unvested and Expected To Vest Outstanding Number (in shares)	2.37	2.37
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 1,740,000	$ 1,740,000
Employee Service Share Based Compensation Nonvested Total Compensation In Year Four		$ 72,000
Share Based Compensation Arrangement By Share Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Number	146,360	146,360
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	460,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Unvested and Expected To Vest Outstanding Number (in shares)	12.42	12.42
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual Forfeiture Rate Percentage		2.00%	2.00%
Minimum [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 2.08	$ 2.08
Maximum [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 2.10	$ 2.10

XML 43 R32.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Details) - Convertible Debt [Member] - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	8,741,536	4,629,842
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,018,733	397,882

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 124 153 1 true 44 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.novelos.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.novelos.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Sheet http://www.novelos.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Statements 3 false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.novelos.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.novelos.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 106 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN Sheet http://www.novelos.com/role/NatureOfBusinessOrganizationAndGoingConcern NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN Notes 6 false false R7.htm 107 - Disclosure - FAIR VALUE Sheet http://www.novelos.com/role/FairValue FAIR VALUE Notes 7 false false R8.htm 108 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.novelos.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 8 false false R9.htm 109 - Disclosure - NOTES PAYABLE Notes http://www.novelos.com/role/NotesPayable NOTES PAYABLE Notes 9 false false R10.htm 110 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.novelos.com/role/StockbasedCompensation STOCK-BASED COMPENSATION Notes 10 false false R11.htm 111 - Disclosure - INCOME TAXES Sheet http://www.novelos.com/role/IncomeTaxes INCOME TAXES Notes 11 false false R12.htm 112 - Disclosure - NET LOSS PER SHARE Sheet http://www.novelos.com/role/NetLossPerShare NET LOSS PER SHARE Notes 12 false false R13.htm 113 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.novelos.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 114 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Policies) Sheet http://www.novelos.com/role/NatureOfBusinessOrganizationAndGoingConcernPolicies NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Policies) Policies 14 false false R15.htm 115 - Disclosure - FAIR VALUE (Tables) Sheet http://www.novelos.com/role/FairValueTables FAIR VALUE (Tables) Tables http://www.novelos.com/role/FairValue 15 false false R16.htm 116 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.novelos.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.novelos.com/role/StockholdersEquity 16 false false R17.htm 117 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.novelos.com/role/StockbasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.novelos.com/role/StockbasedCompensation 17 false false R18.htm 118 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.novelos.com/role/NetLossPerShareTables NET LOSS PER SHARE (Tables) Tables http://www.novelos.com/role/NetLossPerShare 18 false false R19.htm 119 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Details Textual) Sheet http://www.novelos.com/role/NatureOfBusinessOrganizationAndGoingConcernDetailsTextual NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Details Textual) Details http://www.novelos.com/role/NatureOfBusinessOrganizationAndGoingConcernPolicies 19 false false R20.htm 120 - Disclosure - FAIR VALUE (Details) Sheet http://www.novelos.com/role/FairValueDetails FAIR VALUE (Details) Details http://www.novelos.com/role/FairValueTables 20 false false R21.htm 121 - Disclosure - FAIR VALUE (Details 1) Sheet http://www.novelos.com/role/FairValueDetails1 FAIR VALUE (Details 1) Details http://www.novelos.com/role/FairValueTables 21 false false R22.htm 122 - Disclosure - FAIR VALUE (Details 2) Sheet http://www.novelos.com/role/FairValueDetails2 FAIR VALUE (Details 2) Details http://www.novelos.com/role/FairValueTables 22 false false R23.htm 123 - Disclosure - FAIR VALUE (Details 3) Sheet http://www.novelos.com/role/FairValueDetails3 FAIR VALUE (Details 3) Details http://www.novelos.com/role/FairValueTables 23 false false R24.htm 124 - Disclosure - FAIR VALUE (Details Textual) Sheet http://www.novelos.com/role/FairValueDetailsTextual FAIR VALUE (Details Textual) Details http://www.novelos.com/role/FairValueTables 24 false false R25.htm 125 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://www.novelos.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://www.novelos.com/role/StockholdersEquityTables 25 false false R26.htm 126 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) Sheet http://www.novelos.com/role/StockholdersEquityDetails1 STOCKHOLDERS' EQUITY (Details 1) Details http://www.novelos.com/role/StockholdersEquityTables 26 false false R27.htm 127 - Disclosure - STOCKHOLDERS' EQUITY (Details Textual) Sheet http://www.novelos.com/role/StockholdersEquityDetailsTextual STOCKHOLDERS' EQUITY (Details Textual) Details http://www.novelos.com/role/StockholdersEquityTables 27 false false R28.htm 128 - Disclosure - NOTES PAYABLE (Details Textual) Notes http://www.novelos.com/role/NotesPayableDetailsTextual NOTES PAYABLE (Details Textual) Details http://www.novelos.com/role/NotesPayable 28 false false R29.htm 129 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.novelos.com/role/StockbasedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://www.novelos.com/role/StockbasedCompensationTables 29 false false R30.htm 130 - Disclosure - STOCK-BASED COMPENSATION (Details 1) Sheet http://www.novelos.com/role/StockbasedCompensationDetails1 STOCK-BASED COMPENSATION (Details 1) Details http://www.novelos.com/role/StockbasedCompensationTables 30 false false R31.htm 131 - Disclosure - STOCK-BASED COMPENSATION (Details Textual) Sheet http://www.novelos.com/role/StockbasedCompensationDetailsTextual STOCK-BASED COMPENSATION (Details Textual) Details http://www.novelos.com/role/StockbasedCompensationTables 31 false false R32.htm 132 - Disclosure - NET LOSS PER SHARE (Details) Sheet http://www.novelos.com/role/NetLossPerShareDetails NET LOSS PER SHARE (Details) Details http://www.novelos.com/role/NetLossPerShareTables 32 false false All Reports Book All Reports clrb-20170630.xml clrb-20170630.xsd clrb-20170630_cal.xml clrb-20170630_def.xml clrb-20170630_lab.xml clrb-20170630_pre.xml true true ZIP 50 0001144204-17-042654-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-17-042654-xbrl.zip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Ð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end